

STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)

1. Title of publication: MOLECULAR PHARMACOLOGY; 2. Publication no.: 0026-895X.
3. Date of filing: 10-01-95. 4. Frequency of issue: Monthly; 5. No. of issues published annually: 12; 6. Annual subscription price: \$105.00. 7. Complete mailing address of known office of publication: 351 West Camden Street, Baltimore, MD 21201-2436.
8. Complete mailing address of the headquarters of general business offices of the publisher: 351 West Camden Street, Baltimore, MD 21201-2436.
9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436; Editor: Raymond J. Dingle, Ph.D., Emory University School of Medicine, Rollins Building, 1510 Clifton Road, Atlanta, GA 30322-3090. Managing Editor: Wendy Wiley, Emory University School of Medicine, Rollins Building, 1510 Clifton Road, Atlanta, GA 30322-3090. 10. Owner: American Society of Pharmacology and Experimental Therapeutics, c/o Kay Croker, Executive Director, 9650 Rockville Pike, Bethesda, MD 20814.
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication Name: MOLECULAR PHARMACOLOGY
14. Issue Date for circulation data: August, 1995.
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 2213. (b) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 189; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1334. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 1523. (d) Free distribution by mail (samples, complimentary, and other free copies), 105. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 105. (g) Total distribution (Sum of 15c and 15f) 1628. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 585; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 2213. Percent Paid and/or Requested Circulation (15c/15g x 100) 93.65%. Actual no. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 2412. (b) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 183; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1304. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 1487. (d) Free distribution by mail (samples, complimentary, and other free copies), 85. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 85. (g) Total distribution (Sum of 15c and 15f), 1572. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 840; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 2412. Percent Paid and/or Requested Circulation (15c/15g x 100), 94.59%.
16. This Statement of Ownership will be printed in the December issue of this publication.
17. I certify that the statements made by me above are correct and complete.

Alma J. Wills
Publisher

AUTHOR INDEX FOR VOLUME 48

A

- Abbracchio, M. P., Brambilla, R., Ceruti, S., Kim, H. O., Von Lubitz, D. K. J. E., Jacobson, K. A., and Cattabeni, F. G. Protein-Dependent Activation of Phospholipase C by Adenosine A₃ Receptors in Rat Brain, 1038
- Abdel-Megeed, M. *see* Gupta, M., 658
- Abraham, D. G., Thomas, R. J., and Cooper, A. J. L. Glutamine Transaminase K Is Not a Major Cysteine S-Conjugate β -Lyase of Rat Kidney Mitochondria: Evidence that a High-Molecular Weight Enzyme Fulfills This Role, 855
- Abramson, S. N. *see* Groebe, D. R., 105
- Akuzawa, S. *see* Miyake, A., 407
- Albert, P. R. *see* Lembo, P. M. C., 1024
- Alexander, R. W. *see* Lassègue, B., 601
- Allan, W. P. *see* Ritke, M. K., 798
- Allegra, C. J. *see* Grem, J. L., 305
- Alojipan, S. V. *see* Mohr, F. C., 512
- Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R., and Conti, M. Activation and Selective Inhibition of a Cyclic AMP-Specific Phosphodiesterase, PDE-4D3, 616
- Amara, S. G. *see* Buck, K. J., 1030
- Amend, A. *see* Guan, X.-M., 492
- Anand, R. *see* Gerzanich, V., 774
- Andis, S. L. *see* Habeck, L. L., 326
- Arthur, J. M. *see* Garnovskaya, M. N., 230

B

- Backstrom, J. R. *see* Westphal, R. S., 200
- Baizman, E. *see* Hill, R. J., 98
- Bakthavachalam, V. *see* Lanier, B., 703
- Balcarek, J. M. *see* Belelli, D., 1054
- Ballatori, N., Truong, A. T., Jackson, P. S., Strange, K., and Boyer, J. L. ATP Depletion and Inactivation of an ATP-Sensitive Taurine Channel by Classic Ion Channel Blockers, 472
- Barbour, K. W. *see* Reilly, R. T., 64
- Barker, J. L. *see* Kristiansen, U., 268
- Barnard, E. A. *see* Kidd, E. J., 569
- Barnes, P. J. *see* Seldon, P. M., 747
- Baron, P. *see* Prochaska, H. J., 15
- Barsh, G. S. *see* Link, R. E., 48
- Basile, A. S. *see* Fossom, L. H., 981
- Beall, H. D., Murphy, A. M., Siegel, D., Hargreaves, R. H. J., Butler, J., and Ross, D. Nicotinamide Adenine Dinucleotide (Phosphate): Quinone Oxidoreductase (DT-Diaphorase) as a Target for Bio-reductive Antitumor Quinones: Quinone Cytotoxicity and Selectivity in Human Lung and Breast Cancer Cell Lines, 499
- Beck, W. T. *see* Bhat, U. G., 682
- Belelli, D., Balcarek, J. M., Hope, A. G., Peters, J. A., Lambert, J. J., and Blackburn, T. P. Cloning and Functional Expression of a Human 5-Hydroxytryptamine Type 3A₂ Receptor Subunit, 1054
- Benjamin, C. W. *see* Jones, D. A., 890
- Bennett, E. *see* Rehberg, B., 89
- Berger, F. G. *see* Reilly, R. T., 64
- Berghard, A. *see* Gradin, K., 610
- Betz, H. *see* Schmieden, V., 919
- Bezprozvanny, I., and Tsien, R. W. Voltage-Dependent Blockade of Diverse Types of Voltage-Gated Ca²⁺ Channels Expressed in

- Xenopus* Oocytes by the Ca²⁺ Channel Antagonist Mibefradil (Ro 40-5967), 540
- Bhat, U. G., Winter, M. A., Pearce, H. L., and Beck, W. T. A Structure-Function Relationship Among Reserpine and Yohimbine Analogues in Their Ability to Increase Expression of *mdr1* and P-Glycoprotein in a Human Colon Carcinoma Cell Line, 682
- Bikker, J. *see* Chung, F.-Z., 711
- Birdsall, N. J. M. *see* Lazareno, S., 362
- Blackburn, T. P. *see* Belelli, D., 1054
- Blanner, P. *see* McCormack, S. A., 724
- Blokhin, A. V., Yoo, H.-D., Gerald, R. S., Nagle, D. G., Gerwick, W. H., and Hamel, E. Characterization of the Interaction of the Marine Cyanobacterial Natural Product Curacin A with the Colchicine Site of Tubulin and Initial Structure-Activity Studies with Analogues, 523
- Blond, O. *see* Felder, C. C., 443
- Bloom, F. E. *see* Yu, N., 550
- Boer, R. *see* Borchers, C., 21
- Bon, S. *see* Schalk, I., 1063
- Borchers, C., Ulrich, W.-R., Klemm, K., Ise, W., Gekeler, V., Haas, S., Schödl, A., Conrad, J., Przybylski, M., and Boer, R. B9209-005, an Azido Derivative of the Chemosensitizer Dexniguldipine-HCl, Photolabels P-Glycoprotein, 21
- Bornmann, W. G. *see* Prochaska, H. J., 15
- Boulton, C. L. *see* Garthwaite, J., 184
- Boundy, V. A., Pacheco, M. A., Guan, W., and Molinoff, P. B. Agonists and Antagonists Differentially Regulate the High Affinity State of the D_{2L} Receptor in Human Embryonic Kidney 293 Cells, 956
- Bouvier, M. *see* Labrecque, J., 150
- Boyer, J. L. *see* Ballatori, N., 472
- Boyle, F. T. *see* Westerhof, G. R., 459
- Brambilla, R. *see* Abbracchio, M. P., 1038
- Briley, E. M. *see* Felder, C. C., 443
- Briley, E. M. *see* Priller, J., 288
- Brown, P. J. *see* Gu, Y.-Z., 1004
- Brozowski, S. J. *see* Valenzuela, C. F., 1099
- Buck, K. J., and Amara, S. G. Structural Domains of Catecholamine Transporter Chimeras Involved in Selective Inhibition by Anti-depressants and Psychomotor Stimulants, 1030
- Buell, G. *see* Evans, R. J., 178
- Buller, A. L., Larson, H. C., Morrisett, R. A., and Monaghan, D. T. Glycine Modulates Ethanol Inhibition of Heteromeric N-Methyl-D-Aspartate Receptors Expressed in *Xenopus* Oocytes, 717
- Burnett, J. P. *see* Desai, M. A., 648
- Butler, J. *see* Beall, H. D., 499

C

- Cai, J., Sun, W.-M., and Lu, S. C. Hormonal and Cell Density Regulation of Hepatic γ -Glutamylcysteine Synthetase Gene Expression, 212
- Calmels, T. P. G. *see* Pei, Z. J., 676
- Canonica, P. L. *see* Cavallaro, S., 56
- Capranico, G. *see* De Isabella, P., 30
- Carenini, N. *see* De Isabella, P., 30
- Cattabeni, F. *see* Abbracchio, M. P., 1038
- Cavallaro, S., D'Agata, V., Guardabasso, V., Travalì, S., Stivala, F., and Canonico, P. L. Differentiation Induces Pituitary Adenylate Cyclase-Activating Polypeptide Receptor Expression in PC-12 Cells, 56

- Ceruti, S. *see* Abbracchio, M. P., 1038
 Chang, J. *see* Chen, C.-C., 39
 Chapman, R. S., Whetton, A. D., Chresta, C. M., and Dive, C. Characterization of Drug Resistance Mediated via the Suppression of Apoptosis by Abelson Protein Tyrosine Kinase, 334
 Chase, L. A. *see* Johansen, P. A., 140
 Chaudhary, A. *see* Johansen, T. H., 946
 Chavany, C., Connell, Y., and Neckers, L. Contribution of Sequence and Phosphorothioate Content to Inhibition of Cell Growth and Adhesion Caused by *c-myc* Antisense Oligomers, 738
 Chen, C.-C., Chang, J., and Chen, W.-C. Role of Protein Kinase C Subtypes α and δ in the Regulation of Bradykinin-Stimulated Phosphoinositide Breakdown in Astrocytes, 39
 Chen, C.-C., and Wu, M.-L. Protein Kinase C Isoform δ Is Involved in the Stimulation of the Na⁺-H⁺ Exchanger in C₆ Glioma Cells, 995
 Chen, G., Wright, J. E., and Rosowsky, A. Dihydrofolate Reductase Binding and Cellular Uptake of Nonpolyglutamatable Antifolates: Correlates of Cytotoxicity Toward Methotrexate-Sensitive and -Resistant Human Head and Neck Squamous Carcinoma Cells, 758
 Chen, J., Nye, H. E., Kelz, M. B., Hiroi, N., Nakabeppu, Y., Hope, B. T., and Nestler, E. J. Regulation of Δ FosB and FosB-like Proteins by Electroconvulsive Seizure and Cocaine Treatments, 880
 Chen, W.-C. *see* Chen, C.-C., 39
 Chern, Y., Chiou, J.-Y., Lai, H.-L., and Tsai, M.-H. Regulation of Adenylyl Cyclase Type VI Activity During Desensitization of the A_{2a} Adenosine Receptor-Mediated Cyclic AMP Response: Role for Protein Phosphatase 2A, 1
 Chida, N. *see* Kojo, H., 401
 Chidiac, P. *see* Labrecque, J., 150
 Chiou, J.-Y. *see* Chern, Y., 1
 Chresta, C. M. *see* Chapman, R. S., 334
 Chung, F.-Z., Wu, L.-H., Tian, Y., Vartanian, M. A., Lee, H., Bikker, J., Humblet, C., Pritchard, M. C., Raphy, J., Suman-Chauhan, N., Horwell, D. C., Lalwani, N. D., and Oxender, D. L. Two Classes of Structurally Different Antagonists Display Similar Species Preference for the Human Tachykinin Neurokinin₃ Receptor, 711
 Chung, I. K. *see* Spitzner, J. R., 238
 Ciaccio, P. J., Shen, H., Jaiswal, A. K., Lyttle, M. H., and Tew, K. D. Modulation of Detoxification Gene Expression in Human Colon HT29 Cells by Glutathione-S-Transferase Inhibitors, 639
 Clark, M. *see* Lassègue, B., 601
 Clementi, E., Sciorati, C., and Nisticó, G. Growth Factor-Induced Ca²⁺ Responses Are Differentially Modulated by Nitric Oxide via Activation of a Cyclic GMP-Dependent Pathway, 1068
 Colell, A. *see* García-Ruiz, C., 825
 Colman, P. D. *see* Habeck, L. L., 326
 Connell, Y. *see* Chavany, C., 738
 Connelly, P. *see* Perregaux, D. G., 433
 Conrad, J. *see* Borchers, C., 21
 Conroy, C. W., and Maren, T. H. The Effect of Temperature on the Binding of Sulfonamides to Carbonic Anhydrase Isoenzymes I, II, and IV, 486
 Conti, M. *see* Alvarez, R., 616
 Cooper, A. J. L. *see* Abraham, D. G., 855
 Cory, M. *see* Daniels, A. J., 425
 Côté, T. E. *see* Tang, T., 189
 Coupry, I. *see* Lanier, B., 703
 Cox, B. M. *see* Tang, T., 189
 Creutz, C. E. *see* Pei, Z. J., 676
 Cronan, M. *see* Perregaux, D. G., 433
 Crooke, S. T. *see* Hodges, D., 905
 Cuddy, D. P. *see* Grem, J. L., 305
- D**
- D'Agata, V. *see* Cavallaro, S., 56
 Daniels, A. J., Matthews, J. E., Viveros, O. H., Leban, J. J., Cory, M., and Heyer, D. Structure-Activity Relationship of Novel Pentapeptide Neuropeptide Y Receptor Antagonists Is Consistent with a Noncontinuous Epitope for Ligand-Receptor Binding, 425
 Dávila-García, M. I. *see* Houghtling, R. A., 280
 Dean, D. *see* Perregaux, D. G., 433
 De Bont, H. J. G. M. *see* Van De Water, B., 928
 De Isabella, P., Palumbo, M., Sissi, C., Capranico, G., Carenini, N., Menta, E., Oliva, A., Spinelli, S., Krapcho, A. P., Giuliani, F. C., and Zunino, F. Topoisomerase II DNA Cleavage Stimulation, DNA Binding Activity, Cytotoxicity, and Physico-chemical Properties of 2-Aza- and 2-Aza-oxide-anthracenedione Derivatives, 30
 Delorey, T. M. *see* Huh, K.-H., 666
 Demali, K. A. *see* Valenzuela, C. F., 1099
 Dennis, M. *see* Labrecque, J., 150
 Desai, M. A., Burnett, J. P., Mayne, N. G., and Schoepp, D. D. Cloning and Expression of a Human Metabotropic Glutamate Receptor1 α : Enhanced Coupling on Co-transfection with a Glutamate Transporter, 648
 Deschepper, C. F. *see* Thibault, G., 1046
 Devane, W. A. *see* Priller, J., 288
 Devaud, L. L., Smith, F. D., Grayson, D. R., and Morrow, A. L. Chronic Ethanol Consumption Differentially Alters the Expression of γ -Aminobutyric Acid_A Receptor Subunit mRNAs in Rat Cerebral Cortex: Competitive, Quantitative Reverse Transcriptase-Polymerase Chain Reaction Analysis, 861
 Dimitrijević, S. M., Ryves, W. J., Parker, P. J., and Evans, F. J. Characterization of Phorbol Ester Binding to Protein Kinase C Isoforms, 259
 Dive, C. *see* Chapman, R. S., 334
 Duch, D. S. *see* Rehberg, B., 89
 Dufresne, C. *see* Slipetz, D. M., 352
 Duman, R. S. *see* Hosoda, K., 206
 Dumm, J. M. *see* Groebe, D. R., 105
 Dunlap, R. B. *see* Reilly, R. T., 64
 Dunston, S. K. *see* Mohr, F. C., 512
 Dunwiddie, T. V. *see* Valenzuela, C. F., 1099
- E**
- Ebner, T., Meese, C. O., and Eichelbaum, M. Mechanism of Cytochrome P450 2D6-Catalyzed Sparteine Metabolism in Humans, 1078
 Eglen, R. M. *see* Alvarez, R., 616
 Ehret-Sabatier, L. *see* Schalk, I., 1063
 Eichelbaum, M. *see* Ebner, T., 1078
 Eisenstein, J. *see* Van Leeuwen, D. H., 344
 Elgoyhen, A. B. *see* Johnson, D. S., 194
 Endo, S. *see* Huh, K.-H., 666
 Evans, F. J. *see* Dimitrijević, S. M., 259
 Evans, R. J., Lewis, C., Buell, G., Valera, S., North, R. A., and Surprenant, A. Pharmacological Characterization of Heterologously Expressed ATP-Gated Cation Channels (P_{2X} Purinoceptors), 178
- F**
- Faltynek, C. *see* Hill, R. J., 98
 Farber, J. L. *see* Glascott, P. A., Jr., 80
 Fargin, A. *see* Labrecque, J., 150
 Favreau, L. *see* Slipetz, D. M., 352
 Felder, C. C. *see* Priller, J., 288
 Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., and Mitchell, R. L. Comparison of the Pharmacology and Signal Transduction of the Human Cannabinoid CB₁ and CB₂ Receptors, 443
 Fernández-Checa, J. C. *see* García-Ruiz, C., 825

- Feussner, G. K. *see* Hosoda, K., 206
 French-Constant, R. H. *see* Zhang, H.-G., 835
 Fields, A. P. *see* Ritke, M. K., 798
 Filatov, G. N., and White, M. M. The Role of Conserved Leucines in the M2 Domain of the Acetylcholine Receptor in Channel Gating, 379
 Fischmeister, R. *see* Méry, P.-F., 121
 Fishman, P. H. *see* Hosoda, K., 206
 Fitzgerald, L. R. *see* Hosoda, K., 206
 Fletcher, S. *see* Gerzanich, V., 774
 Foglar, R. *see* Shibata, K., 250
 Forman, S. A., Miller, K. W., and Yellen, G. A Discrete Site for General Anesthetics on a Postsynaptic Receptor, 574
 Forsch, R. A. *see* Westerhof, G. R., 459
 Fossum, L. H., Basile, A. S., and Skolnick, P. Sustained Exposure to 1-Aminocyclopropane-carboxylic acid, a Glycine Partial Agonist, Alters N-Methyl-D[L]-Aspartate Receptor Function and Subunit Composition, 981
 Frazier, J. S. *see* Thomas, J. M., 593
 Freedman, N. J. *see* Pei, G., 173
 Freissmuth, M. *see* Nanoff, C., 806
 Fremneau, R. T., Jr. *see* Shafqat, S., 219
 Friedman, E. *see* Wang, H.-Y., 988
 Fukuchi, J.-I. *see* Williams, K., 1087

G

- Gabel, C. A. *see* Perregaux, D. G., 433
 Galivan, J. *see* Yao, R., 505
 Gallant, M. *see* Slipetz, D. M., 352
 García-Ruiz, C., Colell, A., Morales, A., Kaplowitz, N., and Fernández-Checa, J. C. Role of Oxidative Stress Generated from the Mitochondrial Electron Transport Chain and Mitochondrial Glutathione Status in Loss of Mitochondrial Function and Activation of Transcription Factor Nuclear LONGLONG Factor- κ B, 825
 Gareau, Y. *see* Slipetz, D. M., 352
 Garnovskaya, M. N., Nebigil, C. G., Arthur, J. M., Spurney, R. F., and Raymond, J. R. 5-Hydroxytryptamine_{2A} Receptors Expressed in Rat Renal Mesangial Cells Inhibit Cyclic AMP Accumulation, 230
 Garthwaite, J., Southam, E., Boulton, C. L., Nielsen, E. B., Schmidt, K., and Mayer, B. Potent and Selective Inhibition of Nitric Oxide-Sensitive Guanylyl Cyclase by 1*H*-[1,2,4]Oxadiazolo[4,3- α]-quinoxalin-1-one, 184
 Gekeler, V. *see* Borchers, C., 21
 Geoffroy, F. *see* Grem, J. L., 305
 Gerald, R. S. *see* Blokhin, A. V., 523
 Gerwick, W. H. *see* Blokhin, A. V., 523
 Gerzanich, V., Peng, X., Wang, F., Wells, G., Anand, R., Fletcher, S., and Lindstrom, J. Comparative Pharmacology of Epibatidine: A Potent Agonist for Neuronal Nicotinic Acetylcholine Receptors, 774
 Giasson, E. *see* Leduc, I., 582
 Gienbycz, M. A. *see* Seldon, P. M., 747
 Gilfor, E. *see* Glascott, P. A., Jr., 80
 Giuliani, F. C. *see* De Isabella, P., 30
 Glascott, P. A., Jr., Gilfor, E., and Farber, J. L. Relationship of the Metabolism of Vitamins C and E in Cultured Hepatocytes Treated with *tert*-Butyl Hydroperoxide, 80
 Goeldner, M. *see* Schalk, I., 1063
 Gootz, T. D. *see* Spitzner, J. R., 238
 Gossett, L. S. *see* Habeck, L. L., 326
 Goudreau, N. *see* Jagerschmidt, A., 783
 Gradin, K., Toftgård, R., and Berghard, A. Differential Effects of a Topoisomerase I Inhibitor on Dioxin Inducibility and High-Level Expression of the Cytochrome P450IA1 Gene, 610
 Grahames, C. B. A. *see* Kidd, E. J., 569

- Grant, A. M. *see* Hill, R. J., 98
 Grayson, D. R. *see* Devaud, L. L., 861
 Grem, J. L., Geoffroy, F., Politi, P. M., Cuddy, D. P., Ross, D. D., Nguyen, D., Steinberg, S. M., and Allegra, C. J. Determinants of Sensitivity to 1- β -D-Arabinofuranosylcytosine in HCT 116 and NCI-H630 Human Colon Carcinoma Cells, 305
 Griendling, K. K. *see* Lassegue, B., 601
 Griffin, K. J. *see* Hsu, M.-H., 559
 Groebe, D. R., Dumm, J. M., Levitan, E. S., and Abramson, S. N. α -Conotoxins Selectively Inhibit One of the Two Acetylcholine Binding Sites of Nicotinic Receptors, 105
 Grove, K. L. *see* Thibault, G., 1046
 Gu, Y.-Z., Brown, P. J., Loose-Mitchell, D. S., Stork, P. J. S., and Schonbrunn, A. Development and Use of a Receptor Antibody to Characterize the Interaction between Somatostatin Receptor Subtype 1 and G Proteins, 1004
 Guan, W. *see* Boundy, V. A., 956
 Guan, X.-M., Amend, A., and Strader, C. D. Determination of Structural Domains for G Protein Coupling and Ligand Binding in β_3 -Adrenergic Receptor, 492
 Guardabasso, V. *see* Cavallaro, S., 56
 Guay, D. *see* Slipetz, D. M., 352
 Guiles, J. W. *see* Hill, R. J., 98
 Guillaume, N. *see* Jagerschmidt, A., 783
 Gupta, M., Abdel-Megeed, M., Hoki, Y., Kohlhagen, G., Paull, K., and Pommier, Y. Eukaryotic DNA Topoisomerases Mediated DNA Cleavage Induced by a New Inhibitor: NSC 665517, 658
 Gustafsson, J.-A. *see* Hellmold, H., 630
 Gustafsson, J.-A. *see* Tanaka, H., 938

H

- Haas, S. *see* Borchers, C., 21
 Habeck, L. L., Mendelsohn, L. G., Shih, C., Taylor, E. C., Colman, P. D., Gossett, L. S., Leitner, T. A., Schultz, R. M., Andis, S. L., and Moran, R. G. Substrate Specificity of Mammalian Folylpolyglutamate Synthetase for 5,10-Dideazatetrahydrofolate Analogs, 326
 Haddad, P. *see* Leduc, I., 582
 Hamel, E. *see* Blokhin, A. V., 523
 Hargreaves, R. H. J. *see* Beall, H. D., 499
 Harris, R. A. *see* Valenzuela, C. F., 1099
 Heinemann, S. F. *see* Johnson, D. S., 194
 Hellmold, H., Lamb, J. G., Wyss, A., Gustafsson, J.-A., and Warner, M. Developmental and Endocrine Regulation of P450 Isoforms in Rat Breast, 630
 Hentosh, P., and Tibudan, M. *In Vitro* Transcription of DNA Containing 2-Chloro-2'-deoxyadenosine Monophosphate, 897
 Henzi, V. A. *see* Shafqat, S., 219
 Heyer, D. *see* Daniels, A. J., 425
 Hill, R. J., Grant, A. M., Volberg, W., Rapp, L., Faltynek, C., Miller, D., Pagani, K., Baizman, E., Wang, S., Guiles, J. W., and Krafte, D. S. WIN 17317-3: Novel Nonpeptide Antagonist of Voltage-Activated K⁺ Channels in Human T Lymphocytes, 98
 Hiroi, N. *see* Chen, J., 880
 Hirosumi, J. *see* Kojo, H., 401
 Hodges, D., and Crooke, S. T. Inhibition of Splicing of Wild-Type and Mutated Luciferase-Adenovirus Pre-mRNAs by Antisense Oligonucleotides, 905
 Hoffman, B. B. *see* Thomas, J. M., 593
 Hohenegger, M. *see* Nanoff, C., 806
 Hoki, Y. *see* Gupta, M., 658
 Holtmann, M. H. *see* Ozcelebi, F., 818
 Hope, A. G. *see* Belelli, D., 1054
 Hope, B. T. *see* Chen, J., 880
 Horie, K. *see* Shibata, K., 250

- Horie, K., Itoh, H., and Tsujimoto, G. Hamster α_{1B} -Adrenergic Receptor Directly Activates G_i in the Transfected Chinese Hamster Ovary Cells, 392
- Horowitz, B. *see* Vogalis, F., 1015
- Horwell, D. C. *see* Chung, F.-Z., 711
- Hosoda, K., Fitzgerald, L. R., Vaidya, V. A., Feussner, G. K., Fishman, P. H., and Duman, R. S. Regulation of β_2 -Adrenergic Receptor mRNA and Gene Transcription in Rat C₆ Glioma Cells: Effects of Agonist, Forskolin, and Protein Synthesis Inhibition, 206
- Houghtling, R. A., Dávila-García, M. I., and Kellar, K. J. Characterization of ($\pm$)-[³H]Epibatidine Binding to Nicotinic Cholinergic Receptors in Rat and Human Brain, 280
- Hsu, M.-H., Palmer, C. N. A., Griffin, K. J., and Johnson, E. F. A Single Amino Acid Change in the Mouse Peroxisome Proliferator-Activated Receptor α Alters Transcriptional Responses to Peroxisome Proliferators, 559
- Hu, Z.-W. *see* Thomas, J. M., 593
- Huang, R.-C. Novel Pharmacological Properties of Transient Potassium Currents in Central Neurons Revealed by *N*-Bromoacetamide and Other Chemical Modifiers, 451
- Huh, K.-H., Delorey, T. M., Endo, S., and Olsen, R. W. Pharmacological Subtypes of the γ -Aminobutyric Acid_A Receptors Defined by a γ -Aminobutyric Acid Analogue LONGLONG 4,5,6,7-Tetrahydroisoxazolo[5,4-*c*]pyridin-3-ol, 666
- Humblet, C. *see* Chung, F.-Z., 711
- Humphrey, P. P. A. *see* Kidd, E. J., 569
- Hynes, J. B. *see* Westerhof, G. R., 459

I

- Ichikawa, A. *see* Kotani, M., 869
- Igarashi, K. *see* Williams, K., 1087
- Ise, W. *see* Borchers, C., 21
- Israel, M. *see* McCormack, S. A., 724
- Itoh, H. *see* Horie, K., 392

J

- Jackman, A. L. *see* Westerhof, G. R., 459
- Jackson, M. B. *see* Zhang, H.-G., 835
- Jackson, P. S. *see* Ballatori, N., 472
- Jacobson, K. A. *see* Abbracchio, M. P., 1038
- Jacobson, K. A. *see* Palmer, T. M., 970
- Jagerschmidt, A., Guillaume, N., Goudreau, N., Maigret, B., and Roques, B.-P. Mutation of Asp¹⁰⁰ in the Second Transmembrane Domain of the Cholecystokinin B Receptor Increases Antagonist Binding and Reduces Signal Transduction, 783
- Jaiswal, A. K. *see* Ciaccio, P. J., 639
- Jansen, G. *see* Westerhof, G. R., 459
- Jenco, J. M. *see* Morris, A. J., 532
- Johansen, P. A., Chase, L. A., Sinor, A. D., Koerner, J. F., Johnson, R. L., and Robinson, M. B. Type 4a Metabotropic Glutamate Receptor: Identification of New Potent Agonists and Differentiation from the L-(+)-2-Amino-4-phosphonobutanoic Acid-Sensitive Receptor in the Lateral Perforant Pathway in Rats, 140
- Johansen, T. H., Chaudhary, A., and Verdoorn, T. A. Interactions among GYKI-52466, Cyclothiazide, and Aniracetam at Recombinant AMPA and Kainate Receptors, 946
- Johnson, D. S., Martinez, J., Elgoyhen, A. B., Heinemann, S. F., and McIntosh, J. M. α -Conotoxin ImI Exhibits Subtype-Specific Nicotinic Acetylcholine Receptor Blockade: Preferential Inhibition of Homomeric $\alpha 7$ and $\alpha 9$ Receptors, 194
- Johnson, E. F. *see* Hsu, M.-H., 559
- Johnson, L. R. *see* McCormack, S. A., 724
- Johnson, R. L. *see* Johansen, P. A., 140
- Jones, D. A., Benjamin, C. W., and Linseman, D. A. Activation of Thromboxane and Prostacyclin Receptors Elicits Opposing Ef-

- fects on Vascular Smooth Muscle Cell Growth and Mitogen-Activated Protein Kinase Signaling Cascades, 890
- Joyce, K. E. *see* Felder, C. C., 443

K

- Kaplowitz, N. *see* García-Ruiz, C., 825
- Kashiwagi, K. *see* Williams, K., 1087
- Kathmann, I. *see* Westerhof, G. R., 459
- Kazlauskas, A. *see* Valenzuela, C. F., 1099
- Keith, R. A. *see* Piser, T. M., 131
- Kellar, K. J. *see* Houghtling, R. A., 280
- Kelz, M. B. *see* Chen, J., 880
- Kemper, B. *see* Ramarao, M., 417
- Kerby, J. *see* Priestley, T., 841
- Kiang, J. G. *see* Tang, T., 189
- Kidd, E. J., Grahames, C. B. A., Simon, J., Michel, A. D., Barnard, E. A., and Humphrey, P. P. A. Localization of P_{2X} Purinoceptor Transcripts in the Rat Nervous System, 569
- Kieffer, B. L. *see* Pei, G., 173
- Kim, G. D. *see* MacEwan, D. J., 316
- Kim, H. O. *see* Abbracchio, M. P., 1038
- Klemm, K. *see* Borchers, C., 21
- Kobilka, B. K. *see* Link, R. E., 48
- Koerner, J. F. *see* Johansen, P. A., 140
- Kohlhagen, G. *see* Gupta, M., 658
- Kojo, H., Nakayama, O., Hirosumi, J., Chida, N., Notsu, Y., and Okuhara, M. Novel Steroid 5 α -Reductase Inhibitor FK143: Its Dual Inhibition against the Two Isozymes and Its Effect on Transcription of the Isozyme Genes, 401
- Kotani, M., Tanaka, I., Ogawa, Y., Usui, T., Mori, K., Ichikawa, A., Narumiya, S., Yoshimi, T., and Nakao, K. Molecular Cloning and Expression of Multiple Isoforms of Human Prostaglandin E Receptor EP₃ Subtype Generated by Alternative Messenger RNA Splicing: Multiple Second Messenger Systems and Tissue-Specific Distributions, 869
- Krafte, D. S. *see* Hill, R. J., 98
- Krapcho, A. P. *see* De Isabella, P., 30
- Kristiansen, U., Barker, J. L., and Serafini, R. The Low Efficacy γ -Aminobutyric Acid Type A Agonist 5-(4-Piperidyl)isoxazol-3-ol Opens Brief Cl⁻ Channels in Embryonic Rat Olfactory Bulb Neurons, 268
- Kulatunga, M. *see* Link, R. E., 48

L

- Labelle, M. *see* Slipetz, D. M., 352
- Labrecque, J., Fargin, A., Bouvier, M., Chidiac, P., and Dennis, M. Serotonergic Antagonists Differentially Inhibit Spontaneous Activity and Decrease Ligand Binding Capacity of the Rat 5-Hydroxytryptamine Type 2C Receptor in Sf9 Cells, 150
- Lai, H.-L. *see* Chern, Y., 1
- Lai, Y. *see* Felder, C. C., 443
- Lalwani, N. D. *see* Chung, F.-Z., 711
- Lamb, J. G. *see* Hellmold, H., 630
- Lambert, J. J. *see* Belelli, D., 1054
- Lampe, R. A. *see* Piser, T. M., 131
- Lanier, B., Raddatz, R., Bakthavachalam, V., Couprie, I., Neumeyer, J. L., and Lanier, S. M. Structural and Ligand Recognition Properties of Imidazoline Binding Proteins in Tissues of Rat and Rabbit, 703
- Lanier, S. M. *see* Lanier, B., 703
- Larson, H. C. *see* Buller, A. L., 717
- Lassègue, B., Alexander, R. W., Nickenig, G., Clark, M., Murphy, T. J., and Griendling, K. K. Angiotensin II Down-regulates the Vascular Smooth Muscle AT₁ Receptor by Transcriptional and Post-transcriptional Mechanisms: Evidence for Homologous and Heterologous Regulation, 601

- Laughton, P. *see* Priestley, T., 841
Lazareno, S., and Birdsall, N. J. M. Detection, Quantitation, and Verification of Allosteric Interactions of Agents with Labeled and Unlabeled Ligands at G Protein-Coupled Receptors: Interactions of Strychnine and Acetylcholine at Muscarinic Receptors, 362
Leban, J. J. *see* Daniels, A. J., 425
Le Bourdellès, B. *see* Priestley, T., 841
Leduc, I., Haddad, P., Giasson, E., and Meloche, S. Involvement of a Tyrosine Kinase Pathway in the Growth-Promoting Effects of Angiotensin II on Aortic Smooth Muscle Cells, 582
Lee, H. *see* Chung, F.-Z., 711
Lee, H.-J. *see* Zhang, H.-G., 835
Le Feuvre, Y. *see* Schalk, I., 1063
Lefkowitz, R. J. *see* Pei, G., 173
Leitner, T. A. *see* Habeck, L. L., 326
Lembo, P. M. C., and Albert, P. R. Multiple Phosphorylation Sites Are Required for Pathway-Selective Uncoupling of the 5-Hydroxy-tryptamine_{1A} Receptor by Protein Kinase C, 1024
Levinson, S. R. *see* Rehberg, B., 89
Levitan, E. S. *see* Groebe, D. R., 105
Lewis, C. *see* Evans, R. J., 178
Lindstrom, J. *see* Gerzanich, V., 774
Ling, S. *see* Yao, J.-A., 160
Link, R. E., Stevens, M. S., Kulatunga, M., Scheinin, M., Barsh, G. S., and Kobilka, B. K. Targeted Inactivation of the Gene Encoding the Mouse α_{2C} -Adrenoceptor Homolog, 48
Linseman, D. A. *see* Jones, D. A., 890
Logsdon, C. D. *see* Yang, J., 477
Loose-Mitchell, D. S. *see* Gu, Y.-Z., 1004
Lu, S. C. *see* Cai, J., 212
Lyttle, M. H. *see* Ciaccio, P. J., 639

M

- Ma, A. L. *see* Felder, C. C., 443
MacEwan, D. J., Kim, G. D., and Milligan, G. Analysis of the Role of Receptor Number in Defining the Intrinsic Activity and Potency of Partial Agonists in Neuroblastoma $\times$ Glioma Hybrid NG108-15 Cells Transfected to Express Differing Levels of the Human β_2 -Adrenoceptor, 316
Maciejewski-Lenoir, D. *see* Yu, N., 550
MacKenzie, R. G. *see* Van Leeuwen, D. H., 344
Mackie, K. *see* Felder, C. C., 443
Mackie, K. *see* Priller, J., 288
Magistretti, P. J. *see* Yu, N., 550
Mahlum, C. E. *see* Morris, A. J., 532
Maigret, B. *see* Jagerschmidt, A., 783
Makhlouf, G. M. *see* Murthy, K. S., 293
Makino, I. *see* Tanaka, H., 938
Makino, Y. *see* Tanaka, H., 938
Mansouri, J. *see* Felder, C. C., 443
Mansouri, J. *see* Priller, J., 288
Maren, T. H. *see* Conroy, C. W., 486
Margiotta, J. F., and Pardi, D. Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptors Mediate Cyclic AMP-Dependent Enhancement of Neuronal Acetylcholine Sensitivity, 63
Martinez, J. *see* Johnson, D. S., 194
Massoulie, J. *see* Schalk, I., 1063
Matthews, J. E. *see* Daniels, A. J., 425
Mayer, B. *see* Garthwaite, J., 184
Mayne, N. G. *see* Desai, M. A., 648
McCormack, S. A., Zimmerman, B., Israel, M., Blanner, P., and Johnson, L. R. Structural Requirements of Analogues of Polyamines for Migration and Growth of IEC-6 Cells, 724
McDonald, B. J. *see* Valenzuela, C. F., 1099
McGuirk, P. R. *see* Spitzner, J. R., 238
McIntosh, J. M. *see* Johnson, D. S., 194

- Medzihradsky, F. *see* Yabaluri, N., 690
Meese, C. O. *see* Ebner, T., 1078
Meja, K. *see* Seldon, P. M., 747
Meloche, S. *see* Leduc, I., 582
Mendelsohn, L. G. *see* Habeck, L. L., 326
Menta, E. *see* De Isabella, P., 30
Méry, P.-F., Pavoine, C., Pecker, F., and Fischmeister, R. Erythro-9-(2-Hydroxy-3-nonyl)adenine Inhibits Cyclic GMP-Stimulated Phosphodiesterase in Isolated Cardiac Myocytes, 121
Metters, K. M. *see* Slipetz, D. M., 352
Michel, A. D. *see* Kidd, E. J., 569
Michl, P. *see* Weng, G., 9
Miller, D. *see* Hill, R. J., 98
Miller, K. W. *see* Forman, S. A., 574
Miller, L. J. *see* Ozcelebi, F., 818
Milligan, G. *see* MacEwan, D. J., 316
Mitchell, R. L. *see* Felder, C. C., 443
Mitterauer, T. *see* Nanoff, C., 806
Miyake, A., Mochizuki, S., Takemoto, Y., and Akuzawa, S. Molecular Cloning of Human 5-Hydroxytryptamine₃ Receptor: Heterogeneity in Distribution and Function among Species, 407
Mochizuki, S. *see* Miyake, A., 407
Mohr, F. C., Alojipan, S. V., Dunston, S. K., and Pessah, I. N. The δ Isomer of Hexachlorocyclohexane Induces Rapid Release of the myo-Inositol-1,4,5-trisphosphate-Sensitive Ca^{2+} Store and Blocks Capacitative Ca^{2+} Entry in Rat Basophilic Leukemia Cells, 512
Molinoff, P. B. *see* Boundy, V. A., 956
Monaghan, D. T. *see* Buller, A. L., 717
Morales, A. *see* García-Ruiz, C., 825
Moran, R. G. *see* Habeck, L. L., 326
Mori, K. *see* Kotani, M., 869
Morris, A. J., Rudge, S. A., Mahlum, C. E., and Jenco, J. M. Regulation of Phosphoinositide-3-kinase by G Protein $\beta\gamma$ Subunits in a Rat Osteosarcoma Cell Line, 532
Morrisett, R. A. *see* Buller, A. L., 717
Morrow, A. L. *see* Devaud, L. L., 861
Moss, S. J. *see* Valenzuela, C. F., 1099
Muller, M. T. *see* Spitzner, J. R., 238
Murphy, A. M. *see* Beall, H. D., 499
Murphy, T. J. *see* Lassègue, B., 601
Murray, N. R. *see* Ritke, M. K., 798
Murthy, K. S., and Makhlouf, G. M. Agonist-Mediated Activation of Phosphatidylcholine-Specific Phospholipase C and D in Intestinal Smooth Muscle, 293
Myers, J. *see* Priestley, T., 841

N

- Nagelkerke, J. F. *see* Van De Water, B., 928
Nagle, D. G. *see* Blokhin, A. V., 523
Nakabeppu, Y. *see* Chen, J., 880
Nakao, K. *see* Kotani, M., 869
Nakayama, O. *see* Kojo, H., 401
Nanoff, C., Mitterauer, T., Roka, F., Hohenegger, M., and Freissmuth, M. Species Differences in A₁ Adenosine Receptor/G Protein Coupling: Identification of a Membrane Protein that Stabilizes the Association of the Receptor/G Protein Complex, 806
Narumiya, S. *see* Kotani, M., 869
Nebigil, C. G. *see* Garnovskaya, M. N., 230
Neckers, L. *see* Chavany, C., 738
Nestler, E. J. *see* Chen, J., 880
Neumeyer, J. L. *see* Lanier, B., 703
Nguyen, D. *see* Grem, J. L., 305
Nickenig, G. *see* Lassègue, B., 601
Nielsen, E. B. *see* Garthwaite, J., 184
Nisticó, G. *see* Clementi, E., 1068

- Nogami, M., Whittle, S. M., Romberger, D. J., Rennard, S. I., and Toews, M. L. Lysophosphatidic Acid Regulation of Cyclic AMP Accumulation in Cultured Human Airway Smooth Muscle Cells, 766
- North, R. A. *see* Evans, R. J., 178
- Notsu, Y. *see* Kojo, H., 401
- Nye, H. E. *see* Chen, J., 880

O

- Obika, K. *see* Shibata, K., 250
- Ogawa, S. *see* Shibata, K., 250
- Ogawa, Y. *see* Kotani, M., 869
- Okamoto, K. *see* Tanaka, H., 938
- Okuhara, M. *see* Kojo, H., 401
- Oliva, A. *see* De Isabella, P., 30
- Olsen, R. W. *see* Huh, K.-H., 666
- O'Malley, K. *see* Van Leeuwen, D. H., 344
- O'Neill, G. P. *see* Slipetz, D. M., 352
- Oxender, D. L. *see* Chung, F.-Z., 711
- Ozcelebi, F., Holtmann, M. H., Rentsch, R. U., Rao, R., and Miller, L. J. Agonist-Stimulated Phosphorylation of the Carboxyl-Terminal Tail of the Secretin Receptor, 818

P

- Pacheco, M. A. *see* Boundy, V. A., 956
- Pagani, K. *see* Hill, R. J., 98
- Palmer, C. N. A. *see* Hsu, M.-H., 559
- Palmer, T. M., Poucher, S. M., Jacobson, K. A., and Stiles, G. L. 12⁵I-4-(2-(7-Amino-2-(2-furyl)(1,2,4)triazolo[2,3-a]-(1,3,5)triazin-5-yl-amino)ethyl)phenol, a High Affinity Antagonist Radioligand Selective for the A_{2A} Adenosine Receptor, 970
- Palumbo, M. *see* De Isabella, P., 30
- Pampori, N. A. *see* Waxman, D. J., 790
- Pardi, D. *see* Margiotta, J. F., 63
- Parker, P. J. *see* Dimitrijević, S. M., 259
- Paull, K. *see* Gupta, M., 658
- Pavoine, C. *see* Méry, P.-F., 121
- Pearce, H. L. *see* Bhat, U. G., 682
- Pecker, F. *see* Méry, P.-F., 121
- Pei, G., Kieffer, B. L., Lefkowitz, R. J., and Freedman, N. J. Agonist-Dependent Phosphorylation of the Mouse δ -Opioid Receptor: Involvement of G Protein-Coupled Receptor Kinases But Not Protein Kinase C, 173
- Pei, Z. J., Calmels, T. P. G., Creutz, C. E., and Sebt, S. M. Yeast Cysteine Proteinase Gene *ycp1* Induces Resistance to Bleomycin in Mammalian Cells, 676
- Peng, X. *see* Gerzanich, V., 774
- Perez, J. *see* Popoli, M., 623
- Perregaux, D. G., Dean, D., Cronan, M., Connelly, P., and Gabel, C. A. Inhibition of Interleukin-1 β Production by SKF86002: Evidence of Two Sites of *In Vitro* Activity and of a Time and System Dependence, 433
- Pessah, I. N. *see* Mohr, F. C., 512
- Peters, G. J. *see* Westerhof, G. R., 459
- Peters, J. A. *see* Belelli, D., 1054
- Pinedo, H. M. *see* Westerhof, G. R., 459
- Piser, T. M., Lampe, R. A., Keith, R. A., and Thayer, S. A. ω -Grammotoxin SIA Blocks Multiple, Voltage-Gated, Ca²⁺ Channel Subtypes in Cultured Rat Hippocampal Neurons, 131
- Politi, P. M. *see* Grem, J. L., 305
- Polsky, B. *see* Prochaska, H. J., 15
- Pommier, Y. *see* Gupta, M., 658
- Popoli, M., Vocaturo, C., Perez, J., Smeraldi, E., and Racagni, G. Presynaptic Ca²⁺/Calmodulin-Dependent Protein Kinase II: Autophosphorylation and Activity Increase in the Hippocampus after Long-term Blockade of Serotonin Reuptake, 623

- Poucher, S. M. *see* Palmer, T. M., 970
- Priestley, T., Laughton, P., Myers, J., Le Bourdellès, B., Kerby, J., and Whiting, P. J. Pharmacological Properties of Recombinant Human N-Methyl-D-Aspartate Receptors Comprising NR1a/NR2A and NR1a/NR2B Subunit Assemblies Expressed in Permanently Transfected Mouse Fibroblast Cells, 841
- Priller, J., Briley, E. M., Mansouri, J., Devane, W. A., Mackie, K., and Felder, C. C. Mead Ethanolamide, a Novel Eicosanoid, Is an Agonist for the Central (CB1) and Peripheral (CB2) Cannabinoid Receptors, 288
- Pritchard, M. C. *see* Chung, F.-Z., 711
- Prochaska, H. J., Bornmann, W. G., Baron, P., and Polsky, B. Inhibition of Human Immunodeficiency Virus Type 1 Replication by 7-Methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an *In Vivo* Metabolite of Oltipraz, 15
- Proška, J., and Tuček, S. Competition between Positive and Negative Allosteric Effectors on Muscarinic Receptors, 696
- Przybylski, M. *see* Borchers, C., 21

Q

- Qin, Z.-H., Zhou, L.-W., Zhang, S.-P., Wang, Y., and Weiss, B. D₂ Dopamine Receptor Antisense Oligodeoxynucleotide Inhibits the Synthesis of a Functional Pool of D₂ Dopamine Receptors, 730

R

- Racagni, G. *see* Popoli, M., 623
- Raddatz, R. *see* Lanier, B., 703
- Ram, P. A. *see* Waxman, D. J., 790
- Ramarao, M., and Kemper, B. Substitution at Residue 473 Confers Progesterone 21-Hydroxylase Activity to Cytochrome P450 2C2, 417
- Rao, R. *see* Ozcelebi, F., 818
- Raphy, J. *see* Chung, F.-Z., 711
- Rapp, L. *see* Hill, R. J., 98
- Raymond, J. R. *see* Garnovskaya, M. N., 230
- Rehberg, B., Bennett, E., Xiao, Y.-h., Levinson, S. R., and Duch, D. S. Voltage- and Frequency-Dependent Pentobarbital Suppression of Brain and Muscle Sodium Channels Expressed in a Mammalian Cell Line, 89
- Reilly, R. T., Barbour, K. W., Dunlap, R. B., and Berger, F. G. Biphasic Binding of 5-Fluoro-2'-deoxyuridylate to Human Thymidylate Synthase, 64
- Reis, D. *see* Weng, G., 9
- Ren, H., and Stiles, G. L. Separate Promoters in the Human A₁ Adenosine Receptor Gene Direct the Synthesis of Distinct Messenger RNAs that Regulate Receptor Abundance, 975
- Rennard, S. I. *see* Nogami, M., 766
- Rentsch, R. U. *see* Ozcelebi, F., 818
- Rhee, M. S. *see* Yao, R., 505
- Ritke, M. K., Murray, N. R., Allan, W. P., Fields, A. P., and Yalowich, J. C. Hypophosphorylation of Topoisomerase II in Etoposide (VP-16)-Resistant Human Leukemia K562 Cells Associated with Reduced Levels of β_{II} Protein Kinase C, 798
- Robinson, M. B. *see* Johansen, P. A., 140
- Rocheleau, T. *see* Zhang, H.-G., 835
- Roka, F. *see* Nanoff, C., 806
- Romberger, D. J. *see* Nogami, M., 766
- Roques, B.-P. *see* Jagerschmidt, A., 783
- Rosowsky, A. *see* Chen, G., 758
- Rosowsky, A. *see* Westerhof, G. R., 459
- Ross, D. *see* Beall, H. D., 499
- Ross, D. D. *see* Grem, J. L., 305
- Rudge, S. A. *see* Morris, A. J., 532
- Ryves, W. J. *see* Dimitrijević, S. M., 259

S

- Sakamoto, A. *see* Shibata, K., 250
 Sanders-Bush, E. *see* Westphal, R. S., 200
 Saxena, N. C. *see* Yao, J.-A., 160
 Schalk, I., Ehret-Sabatier, L., Le Feuvre, Y., Bon, S., Massoulie, J., and Goeldner, M. 6-Coumarin Diazonium Salt: A Specific Affinity Label of the *Torpedo* Acetylcholinesterase Peripheral Site, 1063
 Scheinin, M. *see* Link, R. E., 48
 Schmidt, K. *see* Garthwaite, J., 184
 Schmieden, V., and Betz, H. Pharmacology of the Inhibitory Glycine Receptor: Agonist and Antagonist Actions of Amino Acids and Piperidine Carboxylic Acid Compounds, 919
 Schödl, A. *see* Borchers, C., 21
 Schoepp, D. D. *see* Desai, M. A., 648
 Schonbrunn, A. *see* Gu, Y.-Z., 1004
 Schornagel, J. H. *see* Westerhof, G. R., 459
 Schultz, R. M. *see* Habeck, L. L., 326
 Sciorati, C. *see* Clementi, E., 1068
 Sebt, S. M. *see* Pei, Z. J., 676
 Seldin, M. F. *see* Shafqat, S., 219
 Seldon, P. M., Barnes, P. J., Meja, K., and Giembycz, M. A. Suppression of Lipopolysaccharide-Induced Tumor Necrosis Factor- α Generation from Human Peripheral Blood Monocytes by Inhibitors of Phosphodiesterase 4: Interaction with Stimulants of Adenylyl Cyclase, 747
 Serafini, R. *see* Kristiansen, U., 268
 Sette, C. *see* Alvarez, R., 616
 Shafqat, S., Velaz-Faircloth, M., Henzi, V. A., Whitney, K. D., Yang-Feng, T. L., Seldin, M. F., and Freneau, R. T., Jr. Human Brain-Specific L-Proline Transporter: Molecular Cloning, Functional Expression, and Chromosomal Localization of the Gene in Human and Mouse Genomes, 219
 Shapiro, B. H. *see* Waxman, D. J., 790
 Shelton, E. R. *see* Alvarez, R., 616
 Shen, H. *see* Ciaccio, P. J., 639
 Shibata, K., Foglar, R., Horie, K., Obika, K., Sakamoto, A., Ogawa, S., and Tsujimoto, G. KMD-3213, a Novel, Potent, α_{1A} -Adrenoceptor-Selective Antagonist: Characterization Using Recombinant Human α_1 -Adrenoceptors and Native Tissues, 250
 Shih, C. *see* Habeck, L. L., 326
 Siegel, D. *see* Beall, H. D., 499
 Sieghart, W. *see* Slany, A., 385
 Simon, J. *see* Kidd, E. J., 569
 Sinor, A. D. *see* Johansen, P. A., 140
 Sissi, C. *see* De Isabella, P., 30
 Skolnick, P. *see* Fossum, L. H., 981
 Slany, A., Zezula, J., Tretter, V., and Sieghart, W. Rat β_3 Subunits Expressed in Human Embryonic Kidney 293 Cells Form High Affinity [35 S]t-Butylbicyclophosphorothionate Binding Sites Modulated by Several Allosteric LONGLONG Ligands of, 385
 Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M., and Metters, K. M. Activation of the Human Peripheral Cannabinoid Receptor Results in Inhibition of Adenylyl Cyclase, 352
 Smeraldi, E. *see* Popoli, M., 623
 Smith, F. D. *see* Devaud, L. L., 861
 Southam, E. *see* Garthwaite, J., 184
 Spinelli, S. *see* De Isabella, P., 30
 Spitzner, J. R., Chung, I. K., Gootz, T. D., McGuirk, P. R., and Muller, M. T. Analysis of Eukaryotic Topoisomerase II Cleavage Sites in the Presence of the Quinolone CP-115,953 Reveals Drug-Dependent and -Independent Recognition Elements, 238
 Spurney, R. F. *see* Garnovskaya, M. N., 230
 Steinberg, S. M. *see* Grem, J. L., 305
 Stevens, M. S. *see* Link, R. E., 48

- Stevenson, A., Wingrove, P. B., Whiting, P. J., and Wafford, K. A. β -Carboline γ -Aminobutyric Acid $_A$ Receptor Inverse Agonists Modulate γ -Aminobutyric Acid via the Loreclezole Binding Site as well as the Benzodiazepine Site, 965
 Stiles, G. L. *see* Palmer, T. M., 970
 Stiles, G. L. *see* Ren, H., 975
 Stivala, F. *see* Cavallaro, S., 56
 Stork, P. J. S. *see* Gu, Y.-Z., 1004
 Strader, C. D. *see* Guan, X.-M., 492
 Strange, K. *see* Ballatori, N., 472
 Suman-Chauhan, N. *see* Chung, F.-Z., 711
 Sun, W.-M. *see* Cai, J., 212
 Surprenant, A. *see* Evans, R. J., 178

T

- Takemoto, Y. *see* Miyake, A., 407
 Tanaka, H., Makino, Y., Wright, K.-d., Gustafsson, J.-A., Okamoto, K., and Makino, I. Zinc Ions Antagonize the Inhibitory Effect of Aurothiomalate on Glucocorticoid Receptor Function at Physiological Concentrations, 938
 Tanaka, I. *see* Kotani, M., 869
 Tang, T., Kiang, J. G., Côté, T. E., and Cox, B. M. Antisense Oligodeoxynucleotide to the G_{12} Protein α Subunit Sequence Inhibits an Opioid-Induced Increase in the Intracellular Free Calcium Concentration in ND8-47 Neuroblastoma $\times$ Dorsal Root Ganglion Hybrid Cells, 189
 Taylor, E. C. *see* Habeck, L. L., 326
 Tew, K. D. *see* Ciaccio, P. J., 639
 Thayer, S. A. *see* Piser, T. M., 131
 Thibault, G., Grove, K. L., and Deschepper, C. F. Reduced Affinity of Iodinated Forms of Tyr⁰ C-type Natriuretic Peptide for Rat Natriuretic Peptide Receptor B, 1046
 Thomas, J. M., Frazier, J. S., Hu, Z.-W., and Hoffman, B. B. Phosphorylation of Cyclic AMP Response Element-Binding Protein and Induction of c-fos Gene Expression on Withdrawal from Chronic Treatment with Carbachol in NG108-15 Cells, 593
 Thomas, R. J. *see* Abraham, D. G., 855
 Tian, Y. *see* Chung, F.-Z., 711
 Tibudan, M. *see* Hentosh, P., 897
 Toews, M. L. *see* Nogami, M., 766
 Toftgård, R. *see* Gradin, K., 610
 Traval, S. *see* Cavallaro, S., 56
 Tretter, V. *see* Slany, A., 385
 Truong, A. T. *see* Ballatori, N., 472
 Tsai, M.-H. *see* Chern, Y., 1
 Tseng, G.-N. *see* Yao, J.-A., 160
 Tsien, R. W. *see* Bezprozvanny, I., 540
 Tsujimoto, G. *see* Horie, K., 392
 Tsujimoto, G. *see* Shibata, K., 250
 Tuček, S. *see* Proška, J., 696

U

- Ulrich, W.-R. *see* Borchers, C., 21
 Undie, A. S. *see* Wang, H.-Y., 988
 Usui, T. *see* Kotani, M., 869

V

- Vaidya, V. A. *see* Hosoda, K., 206
 Valenzuela, C. F., Kazlauskas, A., Brozowski, S. J., Weiner, J. L., Demali, K. A., McDonald, B. J., Moss, S. J., Dunwiddie, T. V., and Harris, R. A. Platelet-Derived Growth Factor Receptor Is a Novel Modulator of Type A γ -Aminobutyric Acid-Gated Ion Channels, 1099
 Valera, S. *see* Evans, R. J., 178

- Van De Water, B., Zoetewij, J. P., De Bont, H. J. G. M., and Nagelkerke, J. F. Inhibition of Succinate:Ubiquinone Reductase and Decrease of Ubiquinol in Nephrotoxic Cysteine S-Conjugate-Induced Oxidative Cell Injury, 928
- Van Leeuwen, D. H., Eisenstein, J., O'Malley, K., and MacKenzie, R. G. Characterization of a Chimeric Human Dopamine D3/D2 Receptor Functionally Coupled to Adenylyl Cyclase in Chinese Hamster Ovary Cells, 344
- Vartanian, M. A. *see* Chung, F.-Z., 711
- Velaz-Faircloth, M. *see* Shafqat, S., 219
- Verdoorn, T. A. *see* Johansen, T. H., 946
- Viveros, O. H. *see* Daniels, A. J., 425
- Vocaturro, C. *see* Popoli, M., 623
- Vogalis, F., Ward, M., and Horowitz, B. Suppression of Two Cloned Smooth Muscle-Derived Delayed Rectifier Potassium Channels by Cholinergic Agonists and Phorbol Esters, 1015
- Volberg, W. *see* Hill, R. J., 98
- Von Lubitz, D. K. J. E. *see* Abbracchio, M. P., 1038

W

- Wafford, K. A. *see* Stevenson, A., 965
- Wahlestedt, C. *see* Weng, G., 9
- Wang, F. *see* Gerzanich, V., 774
- Wang, H.-Y., Undie, A. S., and Friedman, E. Evidence for the Coupling of G_q Protein to D₁-Like Dopamine Sites in Rat Striatum: Possible Role in Dopamine-Mediated Inositol Phosphate Formation, 988
- Wang, S. *see* Hill, R. J., 98
- Wang, Y. *see* Qin, Z.-H., 730
- Ward, M. *see* Vogalis, F., 1015
- Warner, M. *see* Hellmold, H., 630
- Waxman, D. J., Ram, P. A., Pampori, N. A., and Shapiro, B. H. Growth Hormone Regulation of Male-Specific Rat Liver P450s 2A2 and 3A2: Induction by Intermittent Growth Hormone Pulses in Male but not Female Rats Rendered Growth Hormone Deficient by Neonatal Monosodium Glutamate, 790
- Weiner, J. L. *see* Valenzuela, C. F., 1099
- Weiss, B. *see* Qin, Z.-H., 730
- Wells, G. *see* Gerzanich, V., 774
- Wells, P. G. *see* Winn, L. M., 112
- Weng, G., Yee, F., Michl, P., Reis, D., and Wahlestedt, C. Studies on Neuropeptide Y Receptors in a Mouse Adrenocortical Cell Line, 9
- Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier- and Receptor-Mediated Transport of Folate Antagonists Targeting Folate-Dependent Enzymes: Correlates of Molecular-Structure and Biological Activity, 459
- Westphal, R. S., Backstrom, J. R., and Sanders-Bush, E. Increased Basal Phosphorylation of the Constitutively Active Serotonin 2C Receptor Accompanies Agonist-Mediated Desensitization, 200
- Whetton, A. D. *see* Chapman, R. S., 334
- White, M. M. *see* Filatov, G. N., 379
- Whiting, P. J. *see* Priestley, T., 841
- Whiting, P. J. *see* Stevenson, A., 965
- Whitney, K. D. *see* Shafqat, S., 219
- Whittle, S. M. *see* Nogami, M., 766
- Wilhelm, R. *see* Alvarez, R., 616
- Williams, J. A. *see* Yang, J., 477
- Williams, K., Kashiwagi, K., Fukuchi, J.-I., and Igarashi, K. An Acidic Amino Acid in the N-Methyl-D-Aspartate Receptor that Is Important for Spermine Stimulation, 1087

- Wingrove, P. B. *see* Stevenson, A., 965
- Winn, L. M., and Wells, P. G. Phenytoin-Initiated DNA Oxidation in Murine Embryo Culture, and Embryo Protection by the Antioxidative Enzymes Superoxide Dismutase and Catalase: Evidence for Reactive Oxygen Species-Mediated LONGLONG DNA Oxidation, 112
- Winter, M. A. *see* Bhat, U. G., 682
- Wright, J. E. *see* Chen, G., 758
- Wright, K.-d. *see* Tanaka, H., 938
- Wu, L.-H. *see* Chung, F.-Z., 711
- Wu, M.-L. *see* Chen, C.-C., 995
- Wyss, A. *see* Hellmold, H., 630

X

- Xiao, Y.-h. *see* Rehberg, B., 89

Y

- Yabaluri, N., and Medzihradsky, F. Reversible Modulation of Opioid Receptor Binding in Intact Neural Cells by Endogenous Guanosine Triphosphate, 690
- Yagami, T. Differential Coupling of Glucagon and β -Adrenergic Receptors with the Small and Large Forms of the Stimulatory G Protein, 849
- Yalowich, J. C. *see* Ritke, M. K., 798
- Yang, D. *see* Alvarez, R., 616
- Yang, J., Williams, J. A., Yule, D. I., and Logsdon, C. D. Mutation of Carboxyl-Terminal Threonine Residues in Human m3 Muscarinic Acetylcholine Receptor Modulates the Extent of Sequestration and Desensitization, 477
- Yang-Feng, T. L. *see* Shafqat, S., 219
- Yao, J.-A., Saxena, N. C., Ziai, M. R., Ling, S., and Tseng, G.-N. Effects of *n*-Dodecylguanidine on A-Type Potassium Channels: Role of External Surface Charges in Channel Gating, 160
- Yao, R., Rhee, M. S., and Galivan, J. Effects of γ -Glutamyl Hydrolase on Folyl and Antifolypolyglutamates in Cultured H35 Hepatoma Cells, 505
- Yee, F. *see* Weng, G., 9
- Yellen, G. *see* Forman, S. A., 574
- Yoo, H.-D. *see* Blokhin, A. V., 523
- Yoshimi, T. *see* Kotani, M., 869
- Yu, N., Maciejewski-Lenoir, D., Bloom, F. E., and Magistretti, P. J. Tumor Necrosis Factor- α and Interleukin-1 α Enhance Glucose Utilization by Astrocytes: Involvement of Phospholipase A₂, 550
- Yule, D. I. *see* Yang, J., 477

Z

- Zezula, J. *see* Slany, A., 385
- Zhang, H.-G., Lee, H.-J., Rocheleau, T., French-Constant, R. H., and Jackson, M. B. Subunit Composition Determines Picrotoxin and Bicuculline Sensitivity of *Drosophila* γ -Aminobutyric Acid Receptors, 835
- Zhang, S.-P. *see* Qin, Z.-H., 730
- Zhou, L.-W. *see* Qin, Z.-H., 730
- Ziai, M. R. *see* Yao, J.-A., 160
- Zimmerman, B. *see* McCormack, S. A., 724
- Zoetewij, J. P. *see* Van De Water, B., 928
- Zunino, F. *see* De Isabella, P., 30

SUBJECT INDEX FOR VOLUME 48

A

- A2a desensitization, adenylyl cyclase inhibition in (rat)
 Abelson protein tyrosine kinase, apoptosis suppression by (mouse), 334
 Acetylcholine, strychnine interaction with, at muscarinic receptor (hamster), 362
 Acetylcholine receptor, *see also* Muscarinic acetylcholine receptor; Nicotinic acetylcholine receptor
 channel gating by, conserved leucines in M2 domain and (mouse), 379
 Acetylcholinesterase, 6-coumarin diazonium salt as specific label of (*Torpedo*), 1063
 Adenosine receptor A₁, genetic promoters of (human), 975
 Adenosine receptor A_{2A}, ¹²⁵I-ZM241385 as antagonist radioligand specific for (hamster), 970
 Adenosine receptor A₃, in brain, G protein-dependent phospholipase C activation by (rat), 1038
 Adenosine receptor/G protein coupling, cofactor for (rat), 806
 Adenosine triphosphate, ion channel blocker depletion of (skate), 472
 Adenosine triphosphate-gated cation channel, pharmacological characterization of (human, rat), 178
 Adenylyl cyclase
 cannabinoid receptor inhibition of (human), 352
 dopamine D3/D2 receptor coupled to, in ovary cells (hamster), 344
 inhibition of, in A2a desensitization (rat), 1
 α_1 -Adrenergic receptor, KMD-3213 as antagonist for (human), 250
 α_{1B} -Adrenergic receptor, G_s protein activated by (hamster), 392
 α_{2C} -Adrenergic receptor gene, targeted inactivation of (mouse), 48
 β -Adrenergic receptor, G protein coupling with (rat), 849
 β_3 -Adrenergic receptor
 partial agonism at (human), 316
 regulation of, in glioma cells, forskolin and isoproterenol and (rat), 206
 β_3 -Adrenergic receptor, G protein coupling in (human), 492
 Adrenocortical cell, neuropeptide Y receptor in (mouse), 9
 Airway, smooth muscle cells in, cAMP accumulation in, lysophosphatidic acid regulation of (human), 766
 Alcuronium, strychnine and gallamine competition with, at muscarinic receptor (rat), 696
 γ -Aminobutyric acid
 ion channels gated by, platelet-derived growth factor receptor modulation of (frog, rat), 1099
 pharmacologic analogue subtypes of (cow, rat), 666
 γ -Aminobutyric acid receptor
 β -carboline potentiation of, via loreclezole and benzodiazepine sites (frog), 965
 β_3 -subunits of, TBS binding to, 385
 in cerebral cortex, ethanol consumption and (rat), 861
 sensitivity of, to picrotoxin and bicuculline, 835
 Aminocyclopropanecarboxylic acid, exposure to, NMDA receptor effects of (rat), 981
 AMPA receptor, interactions among GYKI-52466, cyclothiazide, and aniracetam at (frog, human), 946
 Anesthetics, general, nicotinic acetylcholine receptor for (mouse), 574
 Angiotensin II, protein synthesis induced by, in aortic smooth muscle, tyrosine phosphorylation and (rat), 582
 Angiotensin II receptor, in vascular smooth muscle, regulation of (rat), 601

- Aniracetam, GYKI-52466 and cyclothiazide interactions with, at AMPA and kainate receptors (frog, human), 946
 Antidepressants, catecholamine transporter chimera blockade by (human, rat), 1030
 Antifolate, uptake of, dihydrofolate reductase binding and, in head and neck squamous carcinoma cells (human), 758
 Antisense, splicing inhibited by, in luciferase reporters (human), 905
 Aorta, smooth muscle cells in, angiotensin II-induced protein synthesis in, tyrosine phosphorylation and (rat), 582
 Apoptosis, suppression of, by Abelson protein tyrosine kinase (mouse), 334
 Arabinofuranosylcytosine, colon cancer cell sensitivity to (human), 305
 Astrocyte
 bradykinin-stimulated phosphoinositide breakdown in, protein kinase C subtypes α and β in (rat), 39
 glucose uptake in, TNF- α and IL-1 α enhancement of (mouse), 550
 2-Aza-anthracenediones, pharmacological properties of (human), 30

B

- B9209-005, P-glycoprotein photoaffinity labeling by (human), 21
 Basophilic leukemia cell, capacitative Ca²⁺ entry into, δ -hexachlorocyclohexane inhibition of (rat), 512
 Benzodiazepine site, on GABA receptor, β -carboline potentiation via (frog), 965
 Bicuculline sensitivity, of γ -aminobutyric acid receptors (*Drosophila*), 835
 Bleomycin resistance, yeast cysteine proteinase gene induction of (human), 676
 Bradykinin, phosphoinositide breakdown stimulated by, in astrocytes, protein kinase C subtypes α and β in (rat), 39
 Brain
 adenosine A₃ receptors in, G protein-dependent phospholipase C activation by (rat), 1038
 Na⁺ channel in, pentobarbital suppression of (hamster), 89
 nicotinic acetylcholine receptor in, epibatidine binding to in human and chicken, 774
 in human and rat, 280
 proline transporter specific to, molecular cloning and characterization of (human), 219
 Breast, cytochrome P450 isoforms in, development and endocrine regulation of (rat), 630
 Breast cancer, antitumor quinone toxicity in, DT-diaphorase activity and (human), 499
 N-Bromoacetamide, transient potassium currents inhibited by (rat), 451
 N-Bromosuccinimide, transient potassium currents inhibited by (rat), 451
 [³⁵S]t-Butylbicyclophosphorothionate, binding of, to GABA receptors consisting of β_3 subunits (human), 385

C

- Calcium
 capacitative entry of, into basophilic leukemia cells, δ -hexachlorocyclohexane inhibition of (rat), 512
 intracellular, opioid-induced increase in, in ND8-47 cells, 189
 Calcium channel
 ω -grammotxin SIA block of, in hippocampus (rat), 131

- voltage-dependent blockade of, by mibefradil (Ro 40-5967) (frog), 540
- Calcium responses, growth factor-induced, nitric oxide modulation of, via cAMP-dependent pathway (NIH 3T3 cells), 1068
- Calcium/calmodulin-dependent protein kinase II, presynaptic, in treatment with serotonin reuptake blockers (rat), 623
- Cannabinoid receptors
adenylyl cyclase inhibition of (human), 352
mead ethanolamide as agonist for (rat), 288
pharmacology and signal transduction of (human), 443
- Carbachol withdrawal, *c-fos* expression and CREB phosphorylation and (NG108-15 cell), 593
- β -Carboline, GABA receptor potentiation by, via loreclezole and benzodiazepine sites (frog), 965
- Carbonic anhydrase isoenzymes, sulfonamide binding to, temperature and (human), 486
- Cardiac myocyte, cGMP-stimulated phosphodiesterase in, EHNA inhibition of (frog), 121
- Catalase, embryo protection by, from phenytoin-initiated DNA oxidation (mouse), 112
- Catecholamine transporter chimeras, blockade of, by antidepressants and psychomotor stimulants (human, rat), 1030
- Cation channel, ATP-gated, pharmacological characterization of (human, rat), 178
- Central nervous system, P_{2X} purinoceptor in (rat), 569
- Cerebral cortex, GABA_A receptor in, ethanol consumption and (rat), 861
- c-fos* expression, CREB phosphorylation and, in withdrawal from carbachol (NG108-15 cell), 593
- Chloramine T, transient potassium currents inhibited by (rat), 451
- Chloride channel, 4-PIOL gating of, in embryonic olfactory bulb neurons (rat), 268
- Cholecystokinin B receptor, aspartate mutation in second transmembrane of, antagonist binding and signal transduction and (rat), 783
- Cholinergic agonist, suppression of smooth muscle K⁺ channel by (dog), 1015
- Cladribine substitution, in DNA, transcription inhibition by (human), 897
- c-myc* antisense oligomers, inhibition of cell growth and adhesion by, phosphorothioate and (human, mouse), 738
- Cocaine, FosB and FosB-like protein regulation by (rat), 880
- Colchicine site of tubulin, curacin A interaction with (*Lyngbya majuscula*), 523
- Colon, detoxification gene expression in, glutathione S-transferase inhibitors and (human), 639
- Colon carcinoma cell
arabinofuranosylcytosine sensitivity in (human), 305
mdr1 and P-glycoprotein expression in, reserpine and yohimbine analogues and (human), 682
- Complex II, of mitochondrial respiratory chain, oxidative cell injury and (rat), 928
- α -Conotoxin, nicotinic acetylcholine receptor inhibition by in mouse and rat, 194
in *Torpedo*, 105
- 6-Coumarin diazonium salt, as specific label of acetylcholinesterase peripheral site (*Torpedo*), 1063
- CREB, *see* Cyclic adenosine monophosphate response element-binding protein
- Curacin A, interaction of colchicine site of tubulin with (*Lyngbya majuscula*), 523
- Cyclic adenosine monophosphate
accumulation of
in airway smooth muscle cells, lysophosphatidic acid regulation of (human), 766
renal mesangial cell serotonin receptor inhibition of (rat), 230
phosphodiesterase PDE-4D3 specificity for, activation and inhibition of (U937 cells), 616
- Cyclic adenosine monophosphate response, A2a-mediated desensitization of, adenylyl cyclase inhibition in (rat), 1
- Cyclic adenosine monophosphate response element-binding protein, phosphorylation of, *c-fos* expression and, in withdrawal from carbachol (NG108-15 cell), 593
- Cyclic guanosine monophosphate, phosphodiesterase stimulated by, in cardiac myocyte, EHNA inhibition of (frog), 121
- Cyclothiazide, GYKI-52466 and aniracetam interactions with, at AMPA and kainate receptors (frog, human), 946
- CYP1A1* expression, topoisomerase I inhibitor and (human), 610
- CYP4A6*, intrinsic transactivation of, by peroxisome proliferator-activated receptor α (mouse), 559
- Cytochrome P450
isoforms of, development and endocrine regulation of, in breast (rat), 630
male-specific, in liver, GH and (rat), 790
- Cytochrome P450 2C2, conferring of progesterone 21-hydroxylase activity to (rabbit), 417
- Cytochrome P450 2D6, sparteine metabolism catalyzed by (human), 1078

D

- Deoxyribonucleic acid
cladribine substitution in, transcription inhibition by (human), 897
phenytoin-initiated oxidation of, embryo protection from, by superoxide dismutase and catalase (mouse), 112
- Dexniguldipine HCl derivative, P-glycoprotein photoaffinity labeling by (human), 21
- Dideazatetrahydrofolate analogues, folylpolyglutamate synthetase specificity for (human), 326
- Dihydrofolate reductase, binding of, antifolate uptake and, in head and neck squamous carcinoma cells (human), 758
- Dioxin, inducibility of, topoisomerase I inhibitor and (human), 610
- n*-Dodecylguanidine, K⁺ channel surface potential shifted by (frog), 160
- Dopamine D1 receptor, G_q protein coupling to, in striatum (rat), 988
- Dopamine D2 receptor
antisense oligodeoxynucleotide, inhibition of functional D2 receptors by (mouse), 730
regulation of, in embryonic kidney (human), 956
- Dopamine D3/D2 receptor, adenylyl cyclase coupled to, in ovary cells (hamster), 344
- DT-Diaphorase, antitumor quinone toxicity and, in lung and breast cancer cells (human), 499

E

- EHNA, *see* Erythro-9-(2-hydroxy-3-nonyl)adenine
- Electroconvulsive seizure, FosB and FosB-like protein regulation by (rat), 880
- Embryonic kidney, dopamine D2 receptor regulation in (human), 956
- Epibatidine, binding of, to nicotinic acetylcholine receptor, in brain in human and chicken, 774
in human and rat, 280
- Ethanol, glycine-dependent inhibition of NMDA receptor by (frog), 717
- Etoposide resistance, reduced β_{II} protein kinase C and (human), 798

F

- Fibroblast cell, NMDA receptors in, pharmacological properties of (mouse), 841
- FK143, as steroid 5 α -reductase inhibitor (human, rat), 401
- 5-Fluoro-2'-deoxyuridylate, binding of, to thymidylate synthase (human), 72

Folate antagonists, transport of, structure-activity relationships of (human, mouse), 459
 Folyl and antifolypolyglutamates, in hepatoma cell, glutamyl hydro-lase effects on, 505
 Folylpolyglutamate synthetase, specificity of, for dideazatetrahydro-folate analogues (human), 326
 Forskolin, and glioma cell β_2 -adrenergic receptor regulation, 206
 FosB protein, regulation of, by electroconvulsive seizure and cocaine treatment (rat), 880

G

G protein
 adenosine receptor coupling with, cofactor for (rat), 806
 β -adrenergic receptor coupling with (rat), 849
 $\beta\gamma$ subunit of, phosphoinositide 3-kinase regulation by, in osteo-sarcoma cell (rat), 532
 coupling of, in β_2 -adrenergic receptor (human), 492
 phospholipase C activation by adenosine A_3 receptor dependent on, in brain (rat), 1038
 somatostatin receptor subtype 1 interaction with (rat), 1004
 G_q protein, coupling of, to D1-like dopamine receptor, in striatum (rat), 988
 G_s protein, α_{1B} -adrenergic receptor activation of (hamster), 392
 G protein-coupled receptor kinase, δ -opioid receptor phosphorylation and (human), 173
 GABA, *see* γ -Aminobutyric acid
 Gallamine, alcuronium and strychnine competition with, at musca-rinic receptor (rat)
 Gastrointestinal mucosa, migration and growth of cells in, poly-amine analogue structural requirements for (IEC-6 cells), 724
 GH, *see* Growth hormone
 Glioma cell
 β_2 -adrenergic receptor regulation in, forskolin and isoproterenol and (rat), 206
 Na⁺-H exchanger in, protein kinase C δ stimulation of (C₆ cell), 995
 Glucose uptake, in astrocyte, TNF- α and IL-1 α enhancement of (mouse), 550
 Glutamate receptor, metabotropic
 type 1 α , coexpression of, with glutamate transporter (human, rat), 648
 type 4a, phosphonate analogues and (rat), 140
 Glutamate transaminase K, in kidney mitochondria (rat), 855
 Glutamate transporter, coexpression of metabotropic glutamate re-ceptor 1 α with (human, rat), 648
 Glutamyl hydrolase, effects of, on folyl and antifolypolyglutamates, in hepatoma cells (rat), 505
 γ -Glutamylcysteine synthetase, hepatic expression of, regulation of (rat), 212
 Glutathione S-transferase, inhibitors of, colon detoxification gene expression and (human), 639
 Glycine receptor, amino acid pharmacology of (human), 919
 Glycinergic ligands, in neuronal culture (rat), 981
 Glycoprotein, *see* P-glycoprotein
 Glyine, ethanol inhibition of NMDA receptor dependent on (frog), 717
 ω -Grammotoxin SIA, Ca²⁺ channel subtypes blocked by, in hip-pocampus (rat), 131
 Growth factor-induced Ca²⁺ responses, nitric oxide modulation of, via cAMP-dependent pathway (NIH 3T3 cells), 1068
 Growth hormone, male-specific liver P450s and (rat), 790
 Guanosine monophosphate, cyclic, *see* Cyclic guanosine monophos-phate
 Guanosine triphosphate, neural cellular, μ -opioid receptor regula-tion by (SH-SY5Y cells), 690
 Guanylyl cyclase, nitric oxide-sensitive, ODQ inhibition of (rat), 184

GYKI-52466, cyclothiazide and aniracetam interactions with, at AMPA and kainate receptors (frog, human), 946

H

Head and neck squamous carcinoma cell, dihydrofolate reductase binding and antifolate uptake in (human), 758
 Hepatocyte
 endogenous mitochondrial oxidative stress and (rat), 825
 vitamins C and E in, during oxidative stress (rat), 80
 Hepatoma cell, folyl and antifolypolyglutamates in, glutamyl hydro-lase effects on, 505
 δ -Hexachlorocyclohexane, capacitative Ca²⁺ entry into basophilic leukemia cell inhibited by (rat), 512
 Hippocampus, Ca²⁺ channel in, ω -grammotoxin SIA block of (rat), 131
 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one, nitric oxide-sensitive guanylyl cyclase inhibition by (rat), 184
 Human immunodeficiency virus type 1, replication of, oltipraz me-tabolite inhibition of (human), 15
 5-Hydroxytryptamine, *see* Serotonin
 5-Hydroxytryptamine_{1A} receptor, desensitization of, protein kinase C and (human, mouse, rat), 1024
 5-Hydroxytryptamine_{3A} receptor, cloning and expression of (human)

I

IL, *see* Interleukin
 Imidazoline-binding proteins, structure and ligand recognition of (rabbit, rat), 703
 Interleukin 1 α , glucose uptake and, in astrocyte (mouse), 550
 Interleukin 1 β , SKF86002 inhibition of (human), 433
 Intestine, smooth muscle in, phosphatidylcholine-specific phospho-lipase C and D activation in (guinea pig), 293
 Ion channel
 acetylcholine receptor gating of, conserved leucines in M2 domain and (mouse), 379
 GABA-gated, platelet-derived growth factor receptor modulation of (frog, rat), 1099
 Ion channel blockers, ATP depletion by (skate), 472
 Isoproterenol, and glioma cell β_2 -adrenergic receptor regulation, 206
¹²⁵I-ZM241385, as antagonist radioligand specific for adenosine re-ceptor A_{2A} (hamster), 970

K

Kainate receptor, interactions among GYKI-52466, cyclothiazide, and aniracetam at (frog, human), 946
 Kidney, embryonic, dopamine D2 receptor regulation in (human), 956
 Kidney mitochondria, glutamate transaminase K in (rat), 855
 KMD-3213, as α_1 -adrenoceptor-selective antagonist (human), 250

L

Leucine, in M2 domain of acetylcholine receptor, ion channel gating and (mouse), 379
 Leukemia cell
 basophilic, capacitative Ca²⁺ entry into, δ -hexachlorocyclohexane inhibition of (rat), 512
 etoposide resistant, hypophosphorylation of topoisomerase II in, β_{II} protein kinase C and (human), 798
 Lipopolysaccharide, TNF- α generation from monocytes induced by, phosphodiesterase 4 inhibitors and (human), 747
 Liver
 γ -glutamylcysteine synthetase expression in, regulation of (rat), 212
 male-specific cytochrome P450s in, GH and (rat), 790

- Loreclezole site, on GABA receptor, β -carboline potentiation via (frog), 965
 Luciferase reporter, antisense inhibition of splicing in (human), 905
 Lung cancer, antitumor quinone toxicity in, DT-diaphorase activity and (human), 499
 Lysophosphatidic acid, regulation of cAMP accumulation by, in airway smooth muscle cells (human), 766

M

- MAP kinase, *see* Mitogen-activated protein kinase
mdr1 expression, in colon carcinoma cell, reserpine and yohimbine analogues and (human), 682
 Mead ethanolamide, as cannabinoid receptor agonist (rat), 288
 Mesangial cell, renal, serotonin receptor in, cAMP accumulation inhibited by (rat), 230
 Metabotropic glutamate receptor
 type 1 α , coexpression of, with glutamate transporter (human, rat), 648
 type 4a, phosphonate analogues and (rat), 140
 Metal ions, nuclear receptor function and (hamster, human), 938
 Methotrexate sensitivity, of head and neck squamous carcinoma cell, dihydrofolate reductase binding and antifolate uptake and (human), 758
 N-Methyl-D-aspartate receptor
 aminocyclopropanecarboxylic acid exposure and (rat), 981
 glycine-dependent ethanol inhibition of (frog), 717
 NR1 subunit of, spermine stimulation and (frog), 1087
 recombinant, pharmacological properties of (mouse), 841
 Mibefradil (Ro 40-5967), voltage-dependent blockade of Ca²⁺ channel by (frog), 540
 Mitochondria
 kidney, glutamate transaminase K in (rat), 855
 oxidative stress in, in hepatocytes (rat), 825
 Mitochondrial respiratory chain, complex II of, oxidative cell injury and (rat), 928
 Mitogen-activated protein kinase, opposing actions of thromboxane and prostacyclin receptors on (rat), 890
 Monocyte, lipopolysaccharide-induced generation of TNF- α from, phosphodiesterase 4 inhibitors and (human), 747
 Muscarinic acetylcholine receptor, *see also* Acetylcholine receptor
 m3 mutation in, sequestration and desensitization and (human), 477
 Muscarinic receptor
 acetylcholine and strychnine interaction at (hamster), 362
 competition among alcuronium, strychnine, and gallamine at (rat), 696
 Muscle, *see also specific muscle*; Smooth muscle
 Na⁺ channel in, pentobarbital suppression of (hamster), 89
 Myocyte, cardiac, *see* Cardiac myocyte

N

- Na⁺-H exchanger, protein kinase C δ stimulation of, in glioma cell (C₆ cell), 995
 Natriuretic peptide receptor B, reduced Tyr⁰ C-type natriuretic peptide affinity for (rat), 1046
 Neural cell, GTP in, μ -opioid receptor regulation by (SH-SY5Y cells), 690
 Neurokinin_B receptor, antagonist binding to, species differences in (human, rat), 711
 Neuropeptide Y receptor
 in adrenocortical cell (mouse), 9
 antagonists of, structure-activity relationship of (rat), 425
 Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase, antitumor quinone toxicity and, in lung and breast cancer cells (human), 499

- Nicotinic acetylcholine receptor, *see also* Acetylcholine receptor
 α -conotoxin inhibition of
 in mouse and rat, 194
 in *Torpedo*, 105
 epibatidine binding to, in brain
 of human and chicken, 774
 of human and rat, 280
 for general anesthetics (mouse), 574
 PACAP modulation of (chick), 63
 Nitric oxide, modulation of growth factor-induced Ca²⁺ responses, via cAMP-dependent pathway (NIH 3T3 cells), 1068
 Nitric oxide-sensitive guanylyl cyclase, ODQ inhibition of (rat), 184
 NMDA, *see* N-Methyl-D-aspartate
 NSC 665517, as topoisomerase II inhibitor (human), 658
 Nuclear factor κ B, activation of, mitochondrial oxidative stress and, in hepatocytes (rat), 825
 Nuclear receptor, functioning of, metal ions and (hamster, human), 938

O

- ODQ, *see* 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one
 Olfactory bulb neuron, embryonic, 4-PIOL gating of Cl⁻ channel in (rat), 268
 Oltipraz metabolite, HIV-1 replication inhibited by (human), 15
 Opioid, intracellular Ca²⁺ increase and, in ND8-47 cells, 189
 δ -Opioid receptor, phosphorylation of, G protein-coupled receptor kinases and (human), 173
 μ -Opioid receptor, neural cellular GTP regulation of (SH-SY5Y cells), 690
 Osteosarcoma cell, G protein $\beta\gamma$ subunit regulation of phosphoinositide 3-kinase in (rat), 532
 Ovary, dopamine D3/D2 receptor in, adenylyl cyclase coupled to (hamster), 344
 Oxidative cell injury, mitochondrial respiratory chain complex II and (rat), 928
 Oxidative stress
 hepatocyte vitamins C and E during (rat), 80
 mitochondrial, in hepatocytes (rat), 825

P

- PACAP, *see* Pituitary adenylate cyclase-activating polypeptide
 Pentobarbital, brain and muscle Na⁺ channel suppression by (hamster), 89
 Peroxisome proliferator-activated receptor α , intrinsic transactivation of CYP4A6 by (mouse), 559
 P-glycoprotein
 B9209-005 photoaffinity labeling of (human), 21
 in colon carcinoma cell, reserpine and yohimbine analogues and (human), 682
 Phenytoin
 DNA oxidation initiated by, embryo protection from, by superoxide dismutase and catalase (mouse), 112
 teratogenicity of, protection from (mouse), 112
 Phorbol ester
 binding of, to protein kinase C isotypes (baculovirus/insect), 259
 suppression of smooth muscle K⁺ channel by (dog), 1015
 Phosphatidylcholine-specific phospholipase C and D, activation of, in intestinal smooth muscle (guinea pig), 293
 Phosphodiesterase, cGMP-stimulated, in cardiac myocyte, EHNA inhibition of (frog), 121
 Phosphodiesterase 4 inhibitors, and lipopolysaccharide-induced generation of TNF- α from monocytes (human), 747
 Phosphodiesterase PDE-4D3, cAMP-specific, activation and inhibition of (U937 cells), 616

- Phosphoinositide, bradykinin-stimulated breakdown of, in astrocytes, protein kinase C subtypes α and β in (rat), 39
- Phosphoinositide 3-kinase, G protein $\beta\gamma$ subunit regulation of, in osteosarcoma cell (rat), 532
- Phospholipase A_2 , and glucose uptake by astrocyte (mouse), 550
- Phospholipase C, G protein-dependent activation of by adenosine A_3 receptor, in brain (rat), 1038
- Phospholipase C and D, phosphatidylcholine-specific, activation of, in intestinal smooth muscle (guinea pig), 293
- Phosphorothioate, antisense effects of, on growth and adhesion (human, mouse), 738
- Picrotoxin sensitivity, of γ -aminobutyric acid receptors (*Drosophila*), 835
- 4-PIOL (5-(4-Piperidyl)isoxazol-3-ol), gating of Cl^- channel by, in embryonic olfactory bulb neurons (rat), 268
- Pituitary adenylate cyclase-activating polypeptide receptor differentiation-induced expression of (rat), 56
- nicotinic acetylcholine receptor modulation by (chick), 63
- Platelet-derived growth factor receptor, GABA-gated ion channel modulation of (frog, rat), 1099
- Polyamine analogues, structural requirements of, for migration and growth of IEC-6 cells, 724
- Polyglutamates, glutamyl hydrolase effects on, in hepatoma cells (rat), 505
- Potassium channel
- A type, surface potential around, *n*-dodecylguanidine shifting of (frog), 160
 - in smooth muscle, cholinergic and phorbol ester suppression of (dog), 1015
 - in T lymphocyte, WIN 17317-3 inhibition of (human), 98
- Potassium current, transient, inhibition of, by *N*-bromoacetamide, *N*-bromosuccinimide, and chloramine T (rat), 451
- Progesterone 21-hydroxylase, activity of, conferring of, to cytochrome P450 2C2 (rabbit), 417
- Proline transporter, brain-specific, molecular cloning and characterization of (human), 219
- Prostacyclin, MAP kinase activation and (rat), 890
- Prostaglandin E receptor, EP₃ subtype of, molecular cloning and expression of (human), 869
- Protein kinase C
- α and β subtypes of, in bradykinin-stimulated phosphoinositide breakdown, in astrocytes (rat), 39
 - β_{II} , etoposide resistance and (human), 798
 - δ isoform of, Na^+ -H exchanger stimulation by, in glioma cell (C₆ cell), 995
 - 5-hydroxytryptamine_{1A} receptor desensitization and (human, mouse, rat), 1024
 - isotypes of, phorbol ester binding to (baculovirus/insect), 259
- Protein kinase II, Ca^{2+} /calmodulin-dependent, presynaptic, in treatment with serotonin reuptake blockers (rat), 623
- Protein synthesis, angiotensin II-induced, in aortic smooth muscle, tyrosine phosphorylation and (rat), 582
- Protein tyrosine kinase
- Abelson, apoptosis suppression by (mouse), 334
- Psychomotor stimulants, catecholamine transporter chimera blockade by (human, rat), 1030
- P_{2X} purinoceptor
- cloned (human, rat), 178
 - in nervous system (rat), 569

Q

- Quinolone CP115,953, topoisomerase II cleavage sites and (human), 238
- Quinone, antitumor, toxicity of, DT-diaphorase and, in lung and breast cancer cells (human), 499

R

- Renal mesangial cell, serotonin receptor in, cAMP accumulation inhibited by (rat), 230
- Reserpine analogues, *mdr1* and P-glycoprotein expression and, in colon carcinoma cell (human), 682
- Ro 40-5967 (mibefradil), voltage-dependent blockade of Ca^{2+} channel by (frog), 540

S

- Secretin receptor, phosphorylation of (rat), 818
- Serotonin receptor
- constitutively active, desensitization of (NIH/3T3 cells), 200
 - inverse agonism and down-regulation of (rat), 150
 - molecular cloning of (human), 407
 - in renal mesangial cell, cAMP accumulation inhibited by (rat), 230
- Serotonin reuptake blockers, treatment with, Ca^{2+} /calmodulin-dependent protein kinase II in (rat), 623
- Signal transduction, in cholecystokinin B receptor, effect of aspartate mutation in second transmembrane on (rat), 783
- SKF86002, IL-1 β inhibition by (human), 433
- Smooth muscle
- airway, cAMP accumulation in, lysophosphatidic acid regulation of (human), 766
 - aortic, angiotensin II-induced protein synthesis in, tyrosine phosphorylation and (rat), 582
 - intestinal, phosphatidylcholine-specific phospholipase C and D activation in (guinea pig), 293
 - K⁺ channels of, cholinergic and phorbol ester suppression of (dog), 1015
 - vascular, angiotensin II receptor regulation in (rat), 601
- Sodium channel, in brain and muscle, pentobarbital suppression of (hamster), 89
- Somatostatin receptor, subtype 1, G protein interaction with (rat), 1004
- Sparteine metabolism, cytochrome P450 2D6-catalyzed (human), 1078
- Spermine, stimulation of, NDMA receptor NR1 subunit and (frog), 1087
- Steroid 5 α -reductase, FK143 as inhibitor of (human, rat), 401
- Striatum, G_q protein coupling D1-like dopamine receptor in (rat), 988
- Strychnine
- acetylcholine interaction with, at muscarinic receptor (hamster), 362
 - alcuronium and gallamine competition with, at muscarinic receptor (rat)
- Sulfonamide, binding of, to carbonic anhydrase isoenzymes, temperature and (human), 486
- Superoxide dismutase, embryo protection by, from phenytoin-initiated DNA oxidation (mouse), 112

T

- T lymphocyte, K⁺ channel in, WIN 17317-3 inhibition of (human), 98
- Taurine channel, ATP-sensitive, ion channel blocker inactivation of (skate), 472
- TBS, see [³⁵S]t-Butylbicyclophosphorothionate
- Temperature, and sulfonamide binding to carbonic anhydrase isoenzymes (human), 486
- Teratogenesis, of phenytoin, protection from (mouse), 112
- Thromboxane, MAP kinase activation and (rat), 890
- Thymidylate synthase, 5-fluoro-2'-deoxyuridylate binding to (human), 72
- TNF- α , see Tumor necrosis factor α
- Topoisomerase I inhibitor, effects of, on dioxin inducibility and CYP1A1 gene expression (human), 610

Topoisomerase II

- drug-dependent and -independent cleavage sites on (human), 238
- hypophosphorylation of, in etoposide-resistant leukemia cell, β_{II} protein kinase C and (human), 798
- NSC 665517 as inhibitor of (human), 658

Tubulin, colchicine site of, curacin A interaction with (*Lyngbya majuscula*), 523

Tumor necrosis factor α

- glucose uptake and, in astrocyte (mouse), 550
- lipopolysaccharide-induced generation of from monocytes, phosphodiesterase 4 inhibitors and (human), 747

Tyr⁰ C-type natriuretic peptide, reduced affinity of, for natriuretic peptide receptor B (rat), 1046

Tyrosine kinase, *see* Protein tyrosine kinase

Tyrosine phosphorylation, and angiotensin II-induced protein synthesis, in aortic smooth muscle (rat), 582

V

Vascular smooth muscle, angiotensin II receptor regulation in (rat), 601

Vitamins C and E, in hepatocytes, during oxidative stress (rat), 80

W

WIN 17317-3, T lymphocyte K⁺ inhibition by (human), 98

Y

Yeast cysteine proteinase gene, induction of bleomycin resistance by (human), 676

Yohimbine analogues, *mdr1* and P-glycoprotein expression and, in colon carcinoma cell (human), 682


**Copyright © 1995 by the American Society for
Pharmacology and Experimental Therapeutics**

An important resource for everyone
involved in research on the metabolism
of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals

Editor: Raymond F. Novak, Ph.D.,
Wayne State University, Detroit, Michigan



DRUG METABOLISM AND DISPOSITION publishes experimental results from *in vitro* and *in vivo* systems that bring readers significant and original information on the metabolism and disposition of endogenous and exogenous compounds, including the metabolism of therapeutic agents and environmental chemicals. The journal also invites timely reviews, short communications and letters to the Editor. All submissions are refereed to ensure a high standard of publication. The areas covered are:

- metabolism, metabolite identification and mechanisms of metabolite formation
- expression of drug metabolizing enzymes
- regulation of drug metabolizing enzyme gene expression
- toxicological consequences of xenobiotic metabolism
- pharmacokinetics
- pharmacodynamics

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in drug design and all biochemists with interest in drug metabolism, expression or drug metabolizing enzymes and regulation of drug metabolizing enzyme gene expression. *Monthly*

To order by credit card, call TOLL-FREE
1-800-638-6423 in North America. Outside
North America, fax: 1-410-361-8048 or call one
of our international offices: Tokyo (03) 5689-5400,
London 0171-385-2357, Hong Kong 852-2610-2339.

☐ Yes! Please start my subscription.

Avoid future rate increases and ensure
uninterrupted service—enter your
multiyear subscription today!

Drug Metabolism and Disposition (monthly)

- ☐ Individual \$90/year
☐ Institutional \$150/year

(Add \$25 a year for postage outside the U.S.;
in Canada, also add 7 % GST)

- ☐ New Subscription ☐ Renewal
☐ 3 years ☐ 2 years ☐ 1 year

PAYMENT OPTIONS:

- ☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ Am Ex ☐ MasterCard ☐ VISA

Card #

Exp. date

Signature/P.O.#

Name

Address

City/State/Zip

MD, ME, and IL subscribers must add state sales tax. Subscriptions outside
the U.S. must be prepaid in U.S. dollars only. In Japan, contact Igaku-Shoin
MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1996.

Discounts available to members on all ASPET publications. SAVE 10%
when ordering two. SAVE 15% when ordering three. SAVE 20% when
ordering all four.

Return coupon to: Williams & Wilkins, A Waverly Company,
P.O. Box 23291, Baltimore, MD 21203-9990.

DMD 56603

Printed in USA

S6J008Z



Newsworthy and timely articles keep you up-to-date in your field.

MOLECULAR PHARMACOLOGY

Editor: **Raymond Dingleline, Ph.D.**
Emory University School of Medicine
Atlanta, Georgia


Is your special interest receptors and neurotransmitters...drug metabolism...antibiotic and anticancer drug actions...or other areas related to molecular basis of drug action? If so, you should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the papers you read in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anti-cancer drug action. Start your subscription today to ensure access to the most newsworthy papers in your field. *Monthly*

Cut out and send in the coupon or call to start your subscription immediately, **1-800-638-6423** from anywhere in North America. Outside North America, fax 1-410-361-8048 or call one of our international offices: Tokyo (03) 5689-5400, London 0171-385-2357, Hong Kong 852-2610-2339.



Williams & Wilkins
A WAVERLY COMPANY



YES! Enter my subscription.

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

MOLECULAR PHARMACOLOGY(monthly)

☐ Individual: \$115/yr ☐ Institution: \$250/yr
(Please add \$35.00/yr. outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Name _____

Address _____

City/State/Zip _____

Payment Options:

☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ American Express
☐ MasterCard ☐ VISA

Card # _____ Exp. date _____

Signature or P.O. # _____

MD, ME, and IL subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. International orders, fax your order to 1-410-361-8048. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1996.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering four all publications.



Williams & Wilkins
A Waverly Company
P.O. Box 23291
Baltimore, MD 21203-9990

MOL 56625

Printed in USA

S6J030Z

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*; Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.
1990 T. Kendall Harden, *Editor*; Raymond J. Dingleline, R. L. Juliano, James W. Putney, Jr., Kenneth D. Tew, Ronald G. Thurman, *Associate Editors*. University of North Carolina at Chapel Hill.



Williams & Wilkins Quick Copies. Tell us today. Read it tomorrow.

You can get copies of any article published in any Williams & Wilkins journal. It's fast – because we're the primary source, we can fax an article to you within **24 hours** of when we receive your request. It costs less – there are **no copyright fees** and the **cost of faxing is included in the price**. It's affordable – look at the table to the right.

RATES, PER ARTICLE

1–5	pages	\$12
6–10	pages	\$15
11–15	pages	\$18
16–20	pages	\$21
21–25	pages	\$24
26+	pages	\$30

Additional charges
for overnight delivery

Fax, phone, or mail your order to:

Williams & Wilkins
Quick Copies
 351 W. Camden Street
 Baltimore, MD 21201-2436
 Call 1-800-354-9685 (toll free)
 Fax 1-410-528-4458



Williams & Wilkins
 A WAVERLY COMPANY

DDSD 56189

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Therapeutics

Editor: John A. Harvey, Ph.D.

JPET is respected the world over as one of the leading research journals in the field of pharmacology. You'll find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. *Monthly.*

Drug Metabolism and Disposition: The Biological Fate of Chemicals

Editor: Raymond F. Novak, Ph.D.

Drug Metabolism and Disposition publishes experimental results from *in vitro* and *in vivo* systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals. The areas covered are: xenobiotic metabolism, expression of drug metabolizing enzymes, regulation of drug metabolizing enzyme gene expression, pharmacokinetics, pharmacodynamics and toxicological consequences of xenobiotic metabolism. *Monthly.*

Pharmacological Reviews


Editor: David B. Bylund, Ph.D.

Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. *Quarterly.*

Molecular Pharmacology

Editor: Raymond Dingle, Ph.D.

The papers published in **Molecular Pharmacology** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. *Monthly.*



MEMBERS:
SAVE 10% when ordering
two
SAVE 15% when ordering
three
SAVE 20% when ordering
all four publications



Please enter my subscription to the following:

The Journal of Pharmacology and Experimental Therapeutics (monthly)

☐ Individual \$190/year ☐ Institutional \$370/year (Add \$75/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Drug Metabolism and Disposition (monthly)

☐ Individual \$90/year ☐ Institutional \$150/year (Add \$25/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Molecular Pharmacology (monthly)

☐ Individual \$115/year ☐ Institutional \$250/year (Add \$35/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Pharmacological Reviews (quarterly)

☐ Individual \$65/year ☐ Institutional \$115/year ☐ In-training* \$50/year (Add \$20/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

PT 56640

Payment Options:

☐ Check enclosed (payable to Williams & Wilkins)

☐ Bill me ☐ American Express

☐ MasterCard ☐ VISA Card # _____

Exp. date _____ Signature or P.O. # _____

Name _____

Address _____

City/State/Zip _____

* Please indicate institution/status _____

MD, IL, and ME subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1996.

Return coupon to:
Williams & Wilkins
A WAVERLY COMPANY

P.O. Box 23291, Baltimore, MD 21203-9990



For credit card orders, call TOLL FREE: 1-800-638-6423 in North America. Outside North America, fax 1-410-361-8048 or call one of our international offices: Tokyo (03) 5689-5400, London 0171-385-2357, Hong Kong 852-2610-2339.

S6J045Z